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  It was the German pathologist Bardeleben, who was the first to describe hypoplastic 
left heart syndrome (HLHS) more than 160 years ago. In his report about the autopsy 
findings in an infant after dying due to severe asphyxia, he was able to predict the 
reason of death accurately, showing clear understanding of the pathophysiology of 
this disease (Gehrmann et al. 2001). This pathophysiology is exemplified by the 
presence of a hypoplastic left ventricle, which implies the necessity of patent ductus 
arteriosus (PDA) for maintaining the systemic circulation, and consequently the 
survival of the affected patient. Since that time until now a lot of efforts were 
dedicated to understand this syndrome, especially in regard to its molecular 
mechanisms, and probably genetic etiology.   
  HLHS is furthermore characterized by the presence of so called endocardial 
fibroelastosis (EFE), which is a diffuse fibrotic thickening in the endocardium of left 
ventricle (Friehs et al. 2013). Endocardial fibroelastosis is a unique type of cardiac 
fibrosis, which was shown to be derived from aberrant endothelial to mesenchymal 
transition (EndMT) (Xu et al. 2015a). EndMT is known to be essential for the 
formation of cardiac cushions during embryonic life (Eisenberg and Markwald 1995; 
Armstrong and Bischoff 2004). Mutations in several genes related to EndMT, such as 
NOTCH1 that represents an essential regulator for EndMT process during cardiac 
development, were suspected to be involved in the pathogenesis of HLHS (Garg et 
al. 2005; Iascone et al. 2012).  
  Another gene, KIAA0182 (Gse1 in mouse), is found to be mutated in HLHS 
(unpublished data from Iascone lab, Bergamo). However, the function of this gene 
with respect to its role in congenital heart diseases or any other biological process is 
still unknown. Interestingly, KIAA0182 was reported before to be a potential 
component in CoREST complex that is involved together with the transcription factor 
SNAIL in a process similar to EndMT, which is epithelial-mesenchymal transition 
(EMT) (Hakimi et al. 2003; Lin et al. 2010; Yang et al. 2011; Yokoyama et al. 2008). 
This gene is also known to produce one abundant exonic circular RNA (Jeck et al. 
2013; Memczak et al. 2013; Starke et al. 2015), but to the best of our knowledge no 
other study investigated before any possible specific function for this circularized 




  Therefore, taking advantage of the ‘Knockout-first’ mouse model used in this project 
and additional in vitro experiments, this study was performed to answer some 
questions related to the function of KIAA0182, and how it may be involved in HLHS 
or in other diseases, which can be summarized in the following aims: 
 To confirm the correct targeting of Gse1 gene and the structure integrity of 
the trapping cassette in the ‘Knockout-first’ mice. 
 To establish suitable genotyping protocols for the ‘Knockout-first’ mice with 
the mutated allele Gse1tm1a, and for the mice with the mutated allele Gse1tm1c 
after breeding with FLP-recombinase mice. 
 To investigate the phenotype associated with Gse1 trapping and the 
efficiency of the trapping. 
 To elucidate the function of Gse1 gene and its circular RNA with respect to 
its role in EndMT and in HLHS using in vitro and in vivo experiments. 
         
1.1 Hypoplastic left heart syndrome 
1.1.1 Definition 
  Hypoplastic left heart syndrome (HLHS) is a severe form of congenital heart 
diseases, and it is the most common form of single ventricle heart defects (Fixler et 
al. 2010). This syndrome is defined, according to the International Working Group for 
Mapping and Coding of Nomenclatures for Paediatric and Congenital Heart Disease, 
as "a spectrum of cardiac malformations with normally aligned great arteries without 
a common atrioventricular junction, characterized by underdevelopment of the left 
heart with significant hypoplasia of the left ventricle including atresia, stenosis, or 
hypoplasia of the aortic or mitral valve, or both valves, and hypoplasia of the 
ascending aorta and aortic arch". The term hypoplastic left heart complex is used to 
describe the milder forms of this syndrome without valvar stenosis or atresia 
(Tchervenkov et al. 2006). In HLHS patient, the oxygenated blood reaches the right 
atrium through patent foramen ovale (PFO) or nonrestrictive atrial septal defect 
(ASD), and after mixing with the deoxygenated blood, the right ventricle pumps the 
mixed blood to reach the systemic circulation through the patent ductus arteriosus 
(PDA). The endocardium of the left ventricle is commonly thickened, forming 
prominent fibro-elastic tissue called endocardial fibroelastosis (EFE), which 




growing (Friehs et al. 2013). Left untreated, this disease is associated with 100 % 
mortality. HLHS accounts for 20-25 % of deaths because of congenital heart defects, 
representing the first cause of mortality linked to these diseases in infants less than 
one year old (Boneva et al. 2001; Gordon et al. 2008) 
1.1.2 Incidence 
  The incidence of hypoplastic left heart syndrome (HLHS) is estimated to be two to 
three cases per 10,000 live births in the United States, and it is responsible for 2-3 % 
of all congenital heart diseases (Barron et al. 2009; Hoffman and Kaplan 2002; Reller 
et al. 2008). Both males and females are affected with a male predominance (ratio 
about 3:2) (Karamlou et al. 2010; Tikkanen and Heinonen 1994). The disease is 
described in all ethnic groups with no difference reported in the incidence rate related 
to race in several studies (Botto et al. 2001; Shaw et al. 2002; Storch and Mannick 
1992), but one study showed higher rate among Caucasians compared with other 
ethnic groups (Cronk et al. 2004). The reports about any seasonal variation are 
inconsistent, as different studies came to different results (Cronk et al. 2004; 
Eghtesady et al. 2011; Samánek et al. 1991; Tikkanen and Heinonen 1994). The 
reported incidence of this disease may represent underestimation of the true 
incidence, as the rate of spontaneous abortions is not determined and the option of 
elective termination of pregnancy is available in some countries if the disease is 
antenatally diagnosed (Boldt et al. 2002; Cox and Wilson 2007; Hoffman and Kaplan 
2002). 
1.1.3 Pathogenesis and etiology 
  The most prevalent theory to explain the development of hypoplastic left heart 
syndrome depends on the hypothesis that abnormal blood flow through the left side 
of the heart causes cardiac malformations, as it reduces the shear forces applied on 
the developing heart. The evidence for this theory is derived from animal studies 
carried out on chick and zebrafish embryos (Hove et al. 2003; Sedmera et al. 2002), 
and other studies on human fetuses with aortic valve stenosis, which has later 
developed into hypoplastic left heart syndrome (Mäkikallio et al. 2006; McElhinney et 
al. 2009). In embryo, the blood passes through the foramen ovale towards the left 




than that in normal fetuses; suggesting also that the resulting impaired flow 
negatively affects the growth of the left ventricle (Feinstein et al. 2012).       
  However, a primary problem in the myocardium of the left ventricle cannot be 
excluded, as it was also found that successful fetal aortic valvuloplasty for aortic 
stenosis was not associated with improvement in the growth rate of the left ventricle, 
and the biventricular circulation could not be maintained after birth in some cases 
(McElhinney et al. 2009). Another study has also demonstrated that cardiomyocytes 
derived from induced pluripotent stem cells (iPSCs), which were differentiated from 
the skin fibroblasts of a patient with HLHS, showed altered functional characteristics 
and expression levels of several markers. That was shown by comparing these cells 
with cardiomyocytes derived from human embryonic stem cells, and with 
cardiomyocytes derived from the iPSCs differentiated from the dermal fibroblasts of 
unaffected control, suggesting myocyte susceptibility as a contributing factor in the 
pathogenesis of HLHS (Jiang et al. 2014).   
  Another important process to be considered in this context is endothelial to 
mesenchymal transition (EndMT), which is necessary during embryonic heart 
development for the formation of valves and septum (Eisenberg and Markwald 1995). 
It was found that aberrant epigenetically-induced EndMT leads to the development of 
EFE tissue (Xu et al. 2015a), which plays an important role in the pathogenesis of 
HLHS. It was observed that the systolic and diastolic function of the left ventricular in 
borderline left heart disease (moderate severity of HLHS) improved when the EFE 
was resected, making it possible for those patients to avoid the conversion to 
univentricular circulation (Emani et al. 2009). Another study reported that the severity 
of EFE tissue, estimated by echocardiography for midgestation fetuses with evolving 
hypoplastic left heart syndrome, can be correlated with postnatal biventricular 
outcome (McElhinney et al. 2010).  
  The primary causes behind these processes are still not well understood, and 
several environmental and/or genetic risk factors can play a role. Maternal infections 
in the first trimester were reported to be associated with HLHS (Tikkanen and 
Heinonen 1994). Maternal exposure to solvents or degreasing agents, such as paint 
stripper; or the use of certain drugs during pregnancy, such as retinoids, were also 




1998). No link was found between HLHS and maternal smoking, alcohol or coffee 
consumption (Kallen 1999; Tikkanen and Heinonen 1994).  
1.1.4 Genetics 
  A large body of evidence supports the genetic etiology of HLHS. For example, 
several case reports about familial recurrence of HLHS described different modes of 
inheritance with different degrees of penetrance and phenotype severity (Grossfeld 
1999). Higher risk for congenital heart diseases was also observed in the first degree 
relatives of a child diagnosed with HLHS, where most of the affected relatives had 
left-sided obstructive defects. This suggests the presence of common genetic 
etiology for this group of cardiac diseases (Boughman et al. 1987; Loffredo et al. 
2004). More than 30 syndromes contain HLHS as a cardiac phenotype, such as Holt-
Oram syndrome that is caused by mutations in TBX5 gene (Bruneau et al. 1999); 
Rubinstein Taybi syndrome, which is caused by a mutation in CBP gene that is also 
named as CREB Binding Protein (CREBBP) (Hanauer et al. 2002); and Alagille 
syndrome as described in one case report (Robert et al. 2007). Chromosomal 
abnormalities were found in 10 % of children with HLHS, which include trisomies-21, 
-13, and -18; Turner syndrome; and deletion of distal 11q that is also called Jacobsen 
syndrome (Cox and Wilson 2007; Grossfeld et al. 2004; Natowicz et al. 1988).  
  Mutations in different genes were reported to associate with this syndrome. For 
example as described in one case of HLHS with ASD, heterozygous C-T transition at 
nucleotide 642 was found in NKX2-5 gene on chromosome 5, whose homozygous 
disruption was reported to cause abnormal cardiac development and early embryonic 
lethality in mice. However, it is still not certain whether this mutation is pathologically 
significant or not, as it was found in another first degree relative without any cardiac 
defects; and no mutations was reported at all in this gene in a recent study (Elliott et 
al. 2003; Iascone et al. 2012; Lyons et al. 1995). Among other suspected genes, a 
frameshift mutation in NOTCH1 was also described in a family with different heart 
defects including hypoplastic left ventricle (Garg et al. 2005), and two de novo 
mutations in NOTCH1 were additionally found among 53 patients with HLHS 
(Iascone et al. 2012). De novo mutation in KIAA0182 gene causing heterozygous T-
C substitution was also detected in a child with HLHS (unpublished data from 
Iascone lab, Bergamo). Mutations in GJA1 gene (6q22), which is also called 




them had defects in this gene. This was found by analyzing genomic DNA extracted 
from the tissue of hearts explanted from HLHS patients upon heart transplantation 
(Dasgupta et al. 2001). A frameshift mutation in HAND1 gene (5q33) was described 
in 24 out of 31 hypoplastic ventricles. However, in the previously mentioned work of 
Iascone and her colleagues this gene was not found to be mutated using genomic 
DNA isolated from the blood of HLHS patients, suggesting that analyzing blood 
samples might not be sufficient to identify mutations that are responsible for this 
syndrome (Iascone et al. 2012; Reamon-Buettner et al. 2008).  
1.1.5 Clinical presentation 
  The presence and size of interatrial communication and the patency of the ductus 
arteriosus decide the timing of clinical presentation after birth. In most of the patients 
the size of the patent foramen ovale (PFO) or the atrial septum defect (ASD) is 
adequate to guarantee sufficient mixing of oxygenated and deoxygenated blood, and 
the infants are relatively free of symptoms at birth. However, the physiologic closure 
of the arterial duct and the reduction in vascular pulmonary resistance cause a 
dramatic decrease in systemic perfusion, which leads to hypoxia, acidosis and shock. 
HLHS patients with a restricted or no connection between left and right atrium 
manifest at birth with severe cyanosis and cardiogenic shock, and they will not be 
able to survive without an immediate intervention to create an adequate interatrial 
communication (Vlahos et al. 2004). 
1.1.6 Diagnosis and management 
  Echocardiography is usually used to make the postnatal diagnosis. Detailed 
information about the anatomic features should be obtained to direct the future 
management, including the adequacy of the interatrial communication, the function of 
the valves and the size of the ascending aorta. Prenatal diagnosis can also be made 
by fetal echocardiography in the 2nd trimester of pregnancy (Blake et al. 1991), 
which gives the opportunity for parental education, for arranging the delivery in or 
near a specialized center for neonates with HLHS in order to improve their survival 
(Morris et al. 2014), or for the termination of pregnancy. The option of fetal 
intervention is also available in some centers for selected cases with critical aortic 




valvuloplasty in some of those cases is described to prevent the development of 
HLHS (Tworetzky et al. 2004; McElhinney et al. 2009). 
  Apart from the option of no intervention, three major surgical management 
strategies are available postnatally after an initial stabilizing medical therapy, which 
aims to keep the ductus arteriosus patent by prostaglandin E1 (Alprostadil) infusion, 
and in some cases, to create an interatrial communication of sufficient size by 
transcatheter atrial septoplasty. The first surgical option is primary cardiac 
transplantation, which represents a curative option. However, it is restricted by many 
problems including the increased risk of death during waiting for the hearts of infant 
donor, which are very rare (Morrow et al. 1997).  Therefore, the other option of 
palliative surgical therapy, divided in 3 stages, is currently more preferred (Prsa et al. 
2010). This strategy is considered to be palliative as it restores the patient to 
univentricular system using the right ventricle to support in-series systemic and 
pulmonary circulations (Barron et al. 2009). The third option of biventricular repair 
may be considered for patients with mild severity of HLHS (Emani et al. 2009; 
Grossfeld et al. 2009; Tchervenkov et al. 2006)   
    
1.2 Endocardial fibroelastosis (EFE)  
1.2.1 Definition 
  The term endocardial fibroelastosis was presented for the first time almost 70 years 
ago by Weinberg and Himelfarb, who described two cases of infantile cardiomegaly 
in siblings (Weinberg and Himelfarb 1943), where the endocardium appeared milky 
white, glistening and opaque, not thin and transparent as in normal hearts. The 
characteristical pathology in this disorder is represented by different degrees of 
thickening in ventricular endocardium composed of fibroelastotic tissue and manifests 
with symptoms of heart failure in infants and children (Lurie 2010; Sellers et al. 1964; 
Steger et al. 2012). 
1.2.2 Classification 
  Endocardial fibroelastosis can be classified into two types; the secondary form 




syndrome and left ventricular outflow tract obstruction, and likely as a result of these 
defects. The other type is the primary form, which occurs in anatomically normal 
hearts without obvious reason and manifests usually as dilated cardiomyopathy, but it 
may rarely have restrictive or contracted form with left ventricular of small or normal 
size (Ni et al. 1997; Ursell et al. 1984). However, this classification may be 
misleading, as even primary forms are recognized nowadays to be secondary to 
another heart disorder (other than congenital heart diseases), which makes the term 
idiopathic more suitable for the cases without clear cause (Lurie 2010).  
1.2.3 Incidence 
  In 1964 a study reported that the incidence of this disorder in the United States is 
almost one per 5000 live births (Moller et al. 1964). This high rate has dramatically 
decreased in recent decades without identified causes. However, that can be 
attributed probably to the declining of mumps, as it started particularly since the 
introduction of the mumps vaccine (Ni et al. 1997). This potential causal relation 
should be kept in mind, as the children of young adults affected by mumps during 
some epidemics in the last decade may be more susceptible to endocardial 
fibroelastosis (Lurie 2010). Actually, it was recently described that endocardial 
fibroelastosis is found in 25% of children undergoing heart transplantation with the 
diagnosis of dilated cardiomyopathy (Seki et al. 2013). 
1.2.4 Etiology 
  Endocardial fibroelastosis can not be regarded as a distinct disease, but rather as a 
reaction in the endocardium in response to different heart stressors, which are more 
prominent in the left ventricle, where the stress is usually at the highest level (Lurie 
2010; Ursell et al. 1984). Several factors can be involved in the etiology of 
endocardial fibroelastosis. Viral infections, such as infection with Coxsackie or 
mumps virus, are accused to be responsible for the development of this reaction, 
following a stage of myocarditis (Lurie 2010). Non-infectious etiologies can also play 
a role in the occurrence of endocardial fibroelastosis, as it was found to be the result 
of some metabolic abnormalities, such as the absence of lysosomal alpha-
glucosidase or Carnitine deficiency (Dincsoy et al. 1965; Tripp et al. 1981). Placental 
immaturity and myocardial hypoxia in the fetus may also be responsible for this 




anti-La, were reported to be associated with endocardial fibroelastosis together with 
congenital heart block (Nield et al. 2002). Strong association was reported between 
reduced blood flow through the left ventricle during fetal state and the development of 
EFE (Friehs et al. 2013). Additionally, impaired cardiac lymph flow; myocardial 
infarction or physical injury, such as electrical shock, can cause this reaction in the 
heart (Hutchins and Bannayan 1971; Kline et al. 1964; Naguit and Dexheimer 1974).  
However, it should be kept in mind that these triggers may not be able to induce the 
development of EFE without the presence of genetic susceptibility. Mutations in 
several genes, such as tafazzin gene (TAZ) on chromosom X, β-cardiac myosin 
heavy chain gene, muscle LIM protein or a-actinin-2 genes can be linked to this 
disorder (Brady et al. 2006; Kamisago 2006; Mohapatra et al. 2003). 
1.2.5 Pathogenesis 
  The normal endocardium has five layers. Starting from the cavity of the heart 
towards outside, these layers are: the endothelium at first; a layer of loose connective 
tissue with a few cells; a layer of elastin and collagen fibers then another layer of 
smooth muscle cells. The last layer before the myocardium is loose connective tissue 
containing capillaries, unmyelinated nerves and a few cells. Several histologic 
changes can contribute to the pathogenesis of endocardial fibroelastosis, including 
inflammatory, infiltrative or scarring changes in the myocardium related to the primary 
disease. The thickening reaction in the endocardium manifests mostly in the layer of 
smooth muscle cells and in the sub-myocardial layer of loose connective tissue (Lurie 
2010). In a recent study, the role of endothelial-mesenchymal transition was identified 
as a source of fibroblasts producing elastin and collagen fibers in endocardial 
fibroelastosis (Xu et al. 2015a).  
1.2.6 Diagnosis and management 
  Previously, the diagnosis of endocardial fibroelastosis was only possible to be made 
postmortem by autopsy. However, the development in the technology of 
echocardiography made it possible to detect increased echodensity of the 
endocardium with reduced contractility of the ventricle as early as the age of 14 
weeks in pregnancy (Rustico at al. 1995). It was emphasized on the importance of 
using the right terminology in reporting the diagnosis of endocardial fibroelastosis as 




a distinct entity. It is almost impossible to separate the pathological effect of this 
reaction from the effect of the primary disease (Lurie et al. 2010). Similarly, the 
therapeutical interventions are usually directed against the primary etiology in 
combination with symptomatic treatment for heart failure. However, previous report 
described the possibility of completely reversing the development of endocardial 
fibroelastosis, which was caused by maternal anti-Ro and anti-La antibodies, by 
steroids therapy (Raboisson et al. 2005). Resecting the fibroelastic tissue itself was 
shown to have additional benefit regarding the function and the growth of the left 
ventricle after fetal valvotomy for congenital aortic stenosis in non-responding 
patients (Lurie et al. 2010; Tworetzky et al. 2005). 
 
1.3 Endothelial to mesenchymal transition (EndMT)  
1.3.1  Definition of EndMT 
  EndMT is defined as a differentiation process, in which endothelial cells drop off 
their endothelial nature, such as cell-cell junctions and cell polarity, and gain new 
mesenchymal characteristics. This includes the acquiring of invasive and migratory 
capacities to transform into mesenchymal or fibroblast-like cells with elongated 
spindle-shaped morphology, and represents a special form of epithelial-
mesenchymal transition (EMT) (Medici and Kalluri 2012; Yu et al. 2014). This 
process was first described in a study about heart development 40 years ago 
(Markwald et al. 1975). It was thought before that the fibroblast phenotype represents 
the final fate of the endothelial cells undergoing EndMT; but it was recently shown 
that these endothelial cells are able to transform into stem-like cells. That indicates 
that EndMT is a dedifferentiation process, and the dedifferentiated endothelial cells 
can later differentiate again into other types of cells, such as osteoblasts, 
chondrocytes or adipocytes (Medici and Kalluri 2012).    
1.3.2 EndMT stimulants and mechanism  
  Several stimulants can induce the endothelial cells to go into EndMT, such as 
hypoxia, which is shown to cause EndMT in pulmonary artery endothelial cells (Zhu 
et al. 2006). This is thought to be mediated by the downregulation of bone 




role in the development of pulmonary arterial hypertension (Reynolds et al. 2012). 
Another important stimulant is inflammation, as it was found that interleukin-6 and 
tumor necrosis factor-α, which are inflammatory cytokines, can induce EndMT in 
porcine aortic valve endothelial cells, which indicates that this process may be 
involved as an early stage of the aortic valve disease (Mahler et al. 2013). High 
glucose can also cause the loss of endothelial cell markers and transform the human 
aortic endothelial cells into chondrocyte-like cells, and this may be important in the 
development of medial calcification in the vessels of diabetic patients (Tang et al. 
2012; Yu et al. 2014).  
  The exact mechanism of EndMT is still not completely understood, but a strong 
evidence can be obtained from several studies in vitro and in vivo that transforming 
growth factor-beta (TGF-β), among other factors, is important in EndMT induction, 
which is to some degree mediated by the SNAIL family of transcription factors (Frid et 
al. 2002; Kokudo et al. 2008; Medici et al. 2011; Zeisberg et al. 2007b). The TGF-β 
superfamily comprises two groups; the bone morphogenetic proteins (BMPs) and 
TGF-β/activin A subfamilies. TGF-β is involved in the regulation of several biological 
events, such as cell proliferation, cell differentiation and cell apoptosis (Lin et al. 
2012). It has 3 isoforms (TGFβ1, TGFβ2, TGFβ3), which were all shown to be 
involved in EMT, especially TGFβ1, but regarding EndMT, TGFβ2 is more important 
EndMT-inducer compared with TGFβ1, whereas TGFβ3 is found to be not essential 
for EndMT during embryonic development (Medici and Kalluri 2012). The signal of 
TGF-β superfamily members is mediated by different combinations of two types of 
transmembrane receptors, which are type I and type II serine/threonine kinase 
receptors, where the type II receptor phosphorylates the type I receptor upon binding 
to the ligand. There are seven type I receptors and five type II receptors that are 
coded by the human genome, and the specificity to certain ligand is determined by 
the combinations formed from them (van Meeteren and ten Dijke 2012).  
  TGF-β has two type I receptors in endothelial cells working with one TGF-β type II 
receptor. The first receptor is the activin receptor-like kinase 1 (ALK1) that activates 
SMAD 1/5 pathways and can induce endothelial cell proliferation and migration. The 
other type I receptor is ALK5 that activates SMAD 2/3 and plays an inhibitory role for 
the previous events, but it was shown that ALK5 is also necessary for TGF-β/ALK1-




proteins induces their interaction with SMAD 4, the common-mediator (Co) SMAD, 
forming a larger complex that translocates into the nucleus to activate the 
transcription factors that mediate the epigenetic response to TGF-β (van Meeteren 
and ten Dijke 2012). A long list of transcription factors can be involved in the cascade 
of EndMT and EMT in general, such as SNAIL, SLUG, TWIST, zinc finger E-box 
binding homeobox 1 and 2, and FOXC2. These have the common function of 
inhibiting the expression of epithelial- and endothelial-specific proteins; and 
upregulating the mesenchymal markers, and were used previously in several studies 
as markers for EndMT process (Cooley et al. 2014; Elliott et al. 2014; Kalluri and 
Weinberg 2009; Lee et al. 2015; Levet et al. 2015; Piera-Velazquez et al. 2011; Xu et 
al. 2015a; Xu et al. 2015b).   
  It is necessary to mention here that receptors other than previous receptors can 
bind to TGF-β, which are betaglycan and endoglin that are also expressed in 
endothelial cells and play a role in modulating the response to TGF-β mediated by 
type I and type II receptors (Wong et al. 2000). Other pathways are suggested to be 
involved in EndMT and EMT; such as NOTCH pathway, whose signal is important 
during heart development mediated also by SLUG activation (Noseda et al. 2004; 
Timmerman et al. 2004; Yoshimatsu and Watabe 2011). The canonical Wnt signaling 
pathway is also described to induce EndMT in subepicardial endothelial cells after 
myocardial infarction, which may be important for the tissue repair in the infarcted 
area (Aisagbonhi et al. 2011). Additionally, Wnt3a is reported to activate EndMT in 
dermal microvascular endothelial cells, which may be involved in the formation of 
keloids and hypertrophic scars (Lee et al. 2015). 
1.3.3 EndMT markers  
  In addition to using the above mentioned transcription factors as markers for the 
occurrence of EndMT, the expression of downstream genes is also important in this 
context. The suppression of VE-cadherin is a good marker for EndMT as it indicates 
the loss of adherens junctions’ integrity in endothelial cells (Frid et al. 2002). The 
downregulation of CD31, which is also called platelet endothelial cell adhesion 
molecule-1, and Zonula occludens-1 can serve this mission. They are both 
expressed in the intercellular junctions, and their inhibition reflects the process of 
losing the endothelial phenotype. Similarly in case of EMT, the loss of the epithelial 




cadherin, which are important elements in the intercellular junctions in epithelial cells 
(Newman 1994; Noseda et al. 2004; Peinado et al. 2004; Roy et al. 2015; Tian and 
Phillips 2002; Yoshimatsu and Watabe 2011).   
  The gain of mesenchymal characteristics is also useful indicator for EndMT or EMT, 
and the upregulation of several genes represent a marker for these processes, such 
as fibroblast specific protein (FSP)-1, vimentin and alpha-smooth muscle actin (α-
SMA). These markers were used in many studies but with a great debate about their 
specificity and sensitivity, as vimentin can also be positive in endothelial cells; and 
FSP1, which is a specific marker for fibroblasts in the heart, is not sensitive, as not all 
cardiac fibroblasts are FSP1-positive including EndMT-derived fibroblasts (Chen et 
al. 2015; Elliott et al. 2014; Krenning et al. 2010; Zeisberg and Neilson 2009; 
Zeisberg and Kalluri 2010; Zeisberg et al. 2007a; Zeisberg et al. 2007b).  
1.3.4 EndMT and cardiac fibrosis 
  The role of EndMT in cardiovascular development is well known, as it was shown 
that the endocardial cells in the atrio-ventricular canal undergo EndMT generating 
thereby the mesenchymal cells of the heart cushion, which participate in the 
formation of the cardiac valves and septa (Eisenberg and Markwald 1995; Armstrong 
and Bischoff 2004). Additionally, its role in the development of embryonic pulmonary 
artery and aorta was reported (Arciniegas et al. 1989; Arciniegas et al. 2005). 
However, EndMT is also essential in several pathological processes, including 
cancer progression, as it is involved in producing carcinoma-associated fibroblasts 
(Zeisberg et al. 2007a); in addition to its important contribution to fibrogenesis in 
several organs, such as intestines (Rieder et al. 2011), lung (Hashimoto et al. 2010), 
kidney (Zeisberg et al. 2008) and heart (Zeisberg et al. 2007b).  
  Cardiac fibrosis is an essential component in most heart diseases caused by 
different factors such as ischemia, pressure overload, or cardiomyopathy (Beltrami et 
al. 1994; Ho et al. 2010; Vogt et al. 1993). Fibroblasts accumulation with their excess 
secretion of extracellular matrix is the most important factor in scar formation, which 
sequentially has deleterious effect on the fibrotic heart (Krenning et al. 2010). In the 
paper of Zeisberg and her colleagues it was reported that 27% to 35% of all cardiac 
fibroblasts were derived from endothelial cells. That was shown in an animal model 




fibrosis. The induction of EndMT by TGF-β1 was also possible in human coronary 
artery endothelial cells (HCAEC) and could be rescued by BMP-7 (Zeisberg et al. 
2007b). BMP-7 was also suggested to be a useful treatment for endocardial 
fibroelastosis by the inhibition of EndMT, as it was shown as mentioned before that 
fibroblasts in this fibrotic tissue are derived from endocardial endothelial origin. That 
was investigated in a model of heterotopic transplantation using the hearts of 
newborn mice to imitate the reduced flow-state in HLHS (Xu et al. 2015a). Other 
models for cardiac fibrosis suggested a role for EndMT in hypertrophic 
cardiomyopathy (Teekakirikul et al. 2010), and diabetes-induced cardiac fibrosis 
(Widyantoro et al. 2010). This indicates the importance of investigating the potential 
advantages of EndMT inhibition on the prognosis of different cardiac diseases, as it 
was found that Irbesartan in a rat model for diabetes was able to reduce EndMT, 
representing a possible treatment for diabetic cardiomyopathy (Tang et al. 2013).   
 
1.4 KIAA0182 gene 
1.4.1 General information 
  KIAA0182 gene locates on chromosome 16 and consists of 23 exons, mapping to 
the band (16q24.1) in the position 85170003-85676206 on forward strand according 
to the second patch release for the human reference assembly from the genome 
reference consortium (GRCh38.p2), which was released In December 2014. It 
encodes for a protein called Gse1 Coiled-Coil Protein, which consists in its longest 
isoform of 1217 amino acids, and GSE is an acronym from the phrase: genetic 
suppressor element (http://www.ncbi.nlm.nih.gov/gene/23199). The sequences of 
nearly full length transcripts of this gene and other genes isolated from human 
immature myeloid cell line (KG-1) were first reported by Takahiro Nagase and his 
colleagues. Their project in Kazusa DNA Research Institute, from which the 
abbreviation KIAA is derived, aimed to identify the coding sequence of human genes 
that are still unknown. In their study an alternating Arg and Glu repeat was found in 
Gse1 Coiled-Coil Protein, which may indicate that GSE1 protein has RNA-binding 
activity (Nagase et al. 1996; Nagase et al. 2006). 
  KIAA0182 has at least 12 splice variants; 6 of them are protein coding without 




comprising 16 exons with the length of 7495 basepairs (bp). It is almost identical to 
the transcripts Gse1-001 and Gse1-003, but the most important difference is the 
absence of the second exon in the last 2 transcripts, which is circularized to form the 
circular RNA of KIAA0182. Both Gse1-001 and Gse1-003 variants contain 15 exons, 
coding for a smaller proteins with 1144 and 1113 amino acids respectively. The other 
isoforms represent truncated proteins at the 5' end (Gse1-005 and Gse1-011) or the 
3' end (Gse1-006), consisting of 12, 7 or 5 coding exons respectively. The relative 
expression of these isoforms is still not well known. Several other transcripts are 
described which contain retained introns only and do not code for any proteins 
(http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG0000013
1149;r=16:85611409-85676204, Memczak et al. 2013). The RNA of this gene is 
expressed in all major tissues, with relatively high expression in placenta and thymus, 
and no expression in breast. Several orthologs for KIAA0182 can be identified in 
other species. The similarity ratio of these orthologs to the human gene ranges 
between 60% in zebrafish and 97% in chimpanzee (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=GSE1). 
  The reports about the role for this gene in any human disease are very few. It was 
shown in one study that the homozygousity of a single nucleotide polymorphism 
(SNP) within the 3'-UTR of KIAA0182 (rs709805) was associated with increased risk 
for colorectal cancer. The studied SNPs in this study were chosen according to 
several criteria including which mutated genes could have a role in carcinogenesis in 
the colorectum; which SNPs are predicted to locate in micro RNA (miRNA) binding 
sites and which miRNAs are expressed in the colorectum (Landi et al. 2012).  
Another paper described a duplication in chromosome 16, which has the size of 250 
kb comprising seven genes (KIAA0182, GINS2, c16orf74, COX4NB, COX4I1, 
MIR1910 and IRF8), in a woman with mental retardation, spastic paraplegia, severe 
epilepsy, a narrow and arched palate, malar hypoplasia, little subcutaneous fat and 
arachnodactyly (Quéméner-Redon et al. 2013).    
1.4.2 Gse1 gene in mouse 
  The ortholog of KIAA0182 in mouse is called Gse1. It has great similarity to the 
human gene KIAA0182 (84% of nucleotides and 88% of amino acids). 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=GSE1). Mouse Gse1 locates on 




according to the genome reference consortium for mouse 38 patch release 3 
(GRCm38.p3) and consists of 20 exons (http://www.ncbi.nlm.nih.gov/gene/382034).  
  Gse1 is described to have at least 6 splicing variants, 4 of them are protein coding. 
The longest transcript is Gse1-002, comprising 7127 bp in 16 exons, coding for 1223 
amino acids. The transcripts Gse1-001 and Gse1-003 are almost identical to Gse1-
002 transcript, except for small differences in the first coding exon, consisting of 1213 
and 1210 amino acids respectively. The forth coding transcript is very short, 
comprising 3 exons that code for 16 amino acids only 
(http://www.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG000
00031822;r=8:120230536-120581390). This gene is also not broadly studied as its 
human ortholog, and only one study reported that its expression level changes 
temporarily upon induction by retinoic acid in neurites, suggesting an important role 
for this gene in neurite outgrowth (Imai et al. 2005). 
1.4.3 KIAA0182 and circular RNA 
  More than 95% of total RNA is noncoding RNA (ncRNA) (Warner 1999). Circular 
RNAs that are comprised of circularized exonic sequence (also called scrambled 
exons) form an important part of this ncRNA, which were described in a lot of 
previous studies since more than thirty years ago but are still not well understood. 
These circular RNAs are formed by a process called backsplicing, in which a 
downstream 5′ splice site (splice donor) and an upstream 3′ splice site (splice 
acceptor) are joined together (Hsu and Coca-Prados 1979; Lasda and Parker 2014; 
Nigro et al. 1991). It was reported using Genome-wide RNA-sequencing analysis that 
more than 10 % of the transcriped genes in human fibroblasts have backspliced 
exons, producing together more than 25000 different circular RNAs (Jeck et al. 2013).  
  It was thought previously that the expression level of all circular RNA isoforms in 
human is very low compared with the canonical linear RNAs, but recent studies have 
shown that the circular RNA represents the dominant form in many genes with a 
different circular/total RNA ratio. This ratio ranged in the case of KIAA0182 between 
more than 50% in 3 leukocyte cell types (naive  B cells (CD19+), hematopoietic stem 
cells (CD34+) and neutrophils) and almost 100% in other 3 human cell lines (BJ-T, 
HEK293, and HeLa). The circular RNA of KIAA0182 consists of one exon of 219 bp 




site to the acceptor site of this exon (Jeck et al. 2013; Salzman et al. 2012; Starke et 
al. 2015). It was found that this circular RNA is more stable against actinomycin D 
treatment compared with the linear isoforms and not translated (Jeck et al. 2013). It is 
noteworthy to mention here that KIAA0182 circular RNA is conserved in mouse, 
where it is formed from one exon corresponding to the same circularized exon in 
human. This conservation was also described for 69 different circular RNAs, and can 
raise a question about a conserved characteristic in the pre-mRNA that enhances 
backsplicing, suggesting the presence of an important function for this circular RNA 
(Jeck et al. 2013; Lasda and Parker 2014; Memczak et al. 2013).  
  Another important question to be asked in this context is whether all these circular 
RNAs detected by RNA-sequencing are really circles. Several criteria are suggested 
to prove that, which includes reverse transcription polymerase chain reaction (RT-
PCR) using outward-facing primers or Northern blot using a probe spanning the 
scrambled exonic junction. The second criterion for circularity can be the resistance 
of circular RNAs to exonuclease activity, represented in several studies by RNase R 
treatment. Another criterion that would also be useful is that the detected scrambled 
exons do not have the characteristics of linear messenger RNAs (mRNAs), such as 
polyadenylation (Lasda and Parker 2014). It is nowadays not well known, what exact 
roles the circular RNAs can play, which were previously regarded as transcriptional 
noise or RT–PCR artifacts only. According to the available literature, the first well 
proved function is their role as micro RNA (miRNA) sponge, taking advantage of their 
high stability to compete with the mRNAs targeted by this miRNA (Hansen et al. 
2013; Memczak et al. 2013). 
1.4.4 KIAA0182 and CoREST complex 
  The exact function of Gse1 Coiled-Coil Protein is not known until now, but according 
to few studies it is described to have a leucine-zipper domain and it may participate in 
a large multi-proteins complex named as CoREST complex, or BRAF35-HDAC 
complex (BHC) as it is called in some publications (Hakimi et al. 2003; Yang et al. 
2011; Yokoyama et al. 2008). CoREST complex is one of several histone modifying 
complexes, and it regulates the expression of several genes through modulating two 
distinct processes, which are histone acetylation and methylation. Histone acetylation 
on lysine residues, mostly within the N-terminal tail of the histones, causes gene 




chromatin more open. This is regulated by two groups of enzymes: histone 
acetyltransferases and histone deacetylases (HDACs). Histone methylation on lysine 
or arginine residues is associated with both gene activation or inactivation, 
depending on which lysine residue is methylated, and this process is controlled by 
histone methyltransferases and histone demethylases enzymes (Delcuve et al. 2012; 
Hayakawa and Nakayama 2011; Kouzarides 2007; Lakowski et al. 2006). 
   The essential components of CoREST/BHC complex as often described in most 
reviews are the class I HDACs, HDAC1 and/or HDAC2, that have 82% similarity and 
usually exist in homo- or heterodimer; LSD1 that is also named as BHC110 and has 
the function of demethylating dimethylated lysine 4 in histone H3 (H3K4me2); and 
CoREST protein that is also named as the REST corepressor1 and has ELM2 
domain and two SANT domains, which are essential for the interaction with HDAC1 
and hypoacetylated histone tails to stimulate thereby the demethylation activity of 
LSD1 (Brunmeir et al. 2009; Delcuve et al. 2012; Lakowski et al. 2006; Shi et al. 
2005; You et al. 2001; Yu et al. 2003). Additional components can include among 
others: BHC80, which is also called PHF21A and may negatively regulate the activity 
of other components (Shi et al. 2005); BRAF35 (HMG20B), which is mentioned to 
have HMG domain with a binding ability to DNA that is necessary for the repressive 
role of the complex (Hakimi et al. 2002).  
  CoREST complex was first mentioned to be recruited to a DNA site consisting of 
21–23 nucleotides called repressor element 1 (RE1) by RE-1 silencing transcription 
factor (REST). It should play an important role in suppressing the expression of 
neuronal genes in non-neuronal terminally-differentiated cells. It can also play an 
activating role in embryonic stem cells and neural stem cells using help from other 
proteins, such as histone methyltransferases and iBRAF (HMG20A). This protein is 
found to be expressed in the brain and can compete with BRAF35 for binding with 
RE1-containing genes (Delcuve et al. 2012; Lakowski et al. 2006; Wynder et al. 
2005). Another important transcription factor, SNAIL, was found recently to be able to 
recruit CoREST complex through its SNAG domain to suppress the target gene, E-
cadherin, inducing thereby epithelial-mesenchymal transition (EMT) (Lin et al. 2010). 
Similarly, KIAA0182 and other components of CoREST complex were reported to be 
recruited by the SNAG domain of the transcriptional factor Insm1 in AtT-20 cells, and 




study that KIAA0182 plays a regulatory role for this complex (Welcker et al. 2013). All 
this can argue for the presence of several other functions for this complex according 
to its partners, the transcriptional factors involved and the targeted genes.             
1.4.5 KIAA0182 and cardiovascular diseases 
  KIAA0182 could be involved in the pathogenesis of HLHS, as it was found to be 
heterozygously de novo mutated in a child diagnosed with this disease. The 
missense T-C mutation was located in exon 9 from the isoform Gse1-002 causing the 
amino acid leucine to be replaced by proline. This mutation is not one of the 
mentioned SNPs for KIAA0182, which count more than 2200 SNPs 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=GSE1). In silico prediction for 
the mutated protein could not decide whether it is a loss-of-function- or gain-of-
function-mutation (unpublished data from Iascone lab, Bergamo). The importance of 
KIAA0182 in embryonic cardiac development was further confirmed by an experiment 
performed on zebrafish, in which it was shown that KIAA0182 knockout was 
associated with clear cardiac phenotype, represented by reduced size of the ventricle 
and enlarged atrium (unpublished data from Marc-Phillip Hitz, Sanger institute). 
  Additional evidence can be extrapolated from the data about heterozygous mice 
produced for the Europhenome Mouse Project, which has one allele mutated due to 
the insertion of a trapping cassette in Gse1 gene, and this is supposed to create a 
reporter knockout allele. Those mice were found to have hearts with greater weight 
compared with wild type animals in both genders. Other abnormalities were detected 
also in these mice, such as higher systolic blood pressure; in addition to higher pulse 
rate in males, and lower body weight and lower bone density in females 
(http://www.europhenome.org/databrowser/viewer.jsp?set=true&m=true&x=Both-
Split&ln=Gse1&project=All&zygosity=All&m=true&l=10946).    
 
1.5 Gene trap mutagenesis 
1.5.1 Mutagenesis strategies 
  To study the role of one mutation in the pathogenesis of any human disease, or to 
determine the function of one unknown gene several ways can be followed. 




process can be defined as the modification of the genomic DNA of the organism in a 
stable way to get a mutation, which was described for the first time more than 80 
years ago (Muller 1927).  
  Old methods to induce mutagenesis included using X-ray radiation or applying 
chemical mutagenesis by chlorambucil, but these strategies have the problem that 
several genes can be affected, which makes studying one single gene or mutation so 
difficult (Russell et al. 1989; Stanford et al. 2001). In contrast with previous methods, 
ethylnitrosourea (ENU) can cause point mutations or small deletions (20–50 bp) in 
spermatogonial stem cells, but it has the disadvantage that it gives no landmark for 
identifying the mutated genes (Russell et al. 1979; Stanford et al. 2001). The first 
report about using retrovirus to introduce exogenous DNA into the mouse germ cells 
was almost 40 years ago, and it was possible using this method to recover the 
affected genes, opening the road for the wide use of insertional mutagenesis 
(Jaenisch 1976; Spence et al. 1989). The first transgenic mouse was produced in 
1981 by the microinjection of DNA into fertilized oocytes (Gordon and Ruddle 1981; 
Wagner et al. 1981), but identifying the affected gene after that was still not easy, 
which made the strategy of homologous recombination in embryonic stem cells (ES) 
preferred in order to mutate a specific gene (Stanford et al. 2001).  
1.5.2 Gene trapping 
  This strategy can help to produce embryonic stem cells (ES) with random mutations 
by the inserting of a trapping vector into the genomic DNA using electroporation or 
retroviral infection. The reporter after the splicing acceptor inside the trapping vector 
gives a signal indicating its presence in a transcriptionally active gene, and mutating 
thereby this gene by disrupting the splicing process, taking advantage of the polyA 
tail after the reporter. The trapped gene can be identified by sequencing the mRNA 
product using a technique named as rapid amplification of cDNA ends and primers 
located in the trapping cassette. The trapping vector may not be completely 
successful to inactivate the affected gene and hypomorphic allele, rather than a null 
allele, can be generated due to the occurrence of alternative splicing, especially 
when the trapping vector is inserted into an intron. Different vectors can be used, with 
variable characteristics and efficacy, which can be classified basically into 3 types 




  The enhancer-trap vector includes inducible minimum promoter that needs to be 
inserted in an intronic region near to a cis-acting enhancer element (the enhancer of 
affected gene), which derives the expression of the reporter gene β-galactosidase 
(LacZ). It makes the affected gene usually hypomorphic, which made it not frequently 
used. The gene-trap vector produces a fusion transcript between the upstream exon 
of the mutated gene and the promoterless reporter LacZ by the insertion of a trapping 
cassette that contains a splice acceptor (SA) upstream of LacZ in an intronic region 
also. In contrast to that, the promoter-trap vector is inserted into an exon of the 
affected gene producing thereby a fusion protein with the LacZ reporter. It should be 
always kept in mind that the mutated protein generated by these different vectors 
may still be functional depending on the location of its domains (Stanford et al. 2001).    
1.5.3 The ‘Knockout-first’ strategy 
  Several modifications can be applied on the previous trapping vectors, such as the 
integration of homologous recombination sites, facilitating thereby specific genes to 
be targeted. The mutated allele can also be further altered so that it can be reverted 
back to wild type phenotype then reverted again to the null allele-state using different 
systems, such as Cre- and FLP-Recombinase systems, which recognize system-
specific sites inside the trapping cassette. The mechanisms of these two systems are 
similar, including DNA recombination in an irreversible way by strand cleavage, 
exchange and ligation. The targeted sites, LoxP (locus of crossover (x) in P1) and 
FRT (FLP-recombinase recognition target), share common structure, as they consist 
of two inverted repeats of 13 bp size, flanking an asymmetrical core of 8 bp (Branda 
and Dymecki 2004; Skarnes et al. 2011; Stanford et al. 2001; Testa et al. 2004). 
  The ‘Knockout-first’ allele (tm1a as named mostly), whose design is based upon the 
structure of gene-trap vector, takes advantage of these previous advancements and 
it is proposed, as its name suggests, to behave as a null allele from the beginning 
without any further modifications. As it is possible to convert it into a conditional allele 
(tm1c) by FLP-recombinase in ES cells or by breeding with transgenic FLP mice, 
restoring thereby its normal function as wild type allele, this system can possess the 
characteristics of knockout and conditional alleles in one mouse. The conditional 
allele after that, taking advantage of Cre-recombinase, can be reverted into true null 
allele (tm1d) by deleting the critical exon. This is achieved through the generation of 




be controlled temporarily and spatially according to the Cre mice used (Figure 1.1). 
LacZ-tagged null allele (tm1b) can also be obtained directly from the ‘Knockout-first’ 
allele by Cre-recombinase. The trapping cassette is inserted in one of the introns of 
the gene of interest, which should avoid causing deletion of regulatory elements in 
that region, and this needs a lot of efforts to understand the structural details of the 
targeted gene. Computer programs are usually used applying algorithms that predict 
the most suitable site for the insertion of the trapping cassette and the homologous 
recombination strategy around the critical exon. This exon is usually chosen to be the 
5’-most exon that is common to all mRNA isoforms and its deletion can cause 
disruption of at least 50% of the protein structure. These designing criteria are only 
applicable in 60 % of protein-coding genes (Skarnes et al. 2011; Testa et al. 2004).  
 
   
  
 Figure 1.1: The ‘Knockout-first’ allele structure and its possible allelic series 
(Adapted and modified from Ryder et al. 2013). 
  This allele is the most common type of mutated alleles in the collection of embryonic 
stem cells (ES) of the European conditional mouse mutagenesis program and the 
knockout mouse program (EUCOMM/KOMP-CSD), which represents the main 
source for generating targeted mutations in mice by the International Mouse 
Phenotyping Consortium (IMPC). The aims of this program are to produce knockout 
models for all protein-coding genes in the mouse (Brown and Moore 2012; Ryder et 
al. 2013; Skarnes et al. 2011), and the ‘Knockout-first’ mice were recently used in 
several studies as a knockout model without further changes by FLP or Cre mice 
(Maguire et al. 2014; Nijnik et al. 2012; Rainger et al. 2011; Wheway et al. 2013). 
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2. Materials and methods 
2.1 Materials 
2.1.1 Animals 
  In this study, we used mice generated from the embryonic stem cell (ES) resources 
of EUCOMM/KOMP-CSD (cell clone: EPD0557_2_C07, project number: 71610) with 
a C57BL/6NTac background. The mutated allele in these mice (Gse1tm1a(EUCOMM)Wtsi) 
has the design of ‘Knockout-first’ allele, and it is produced by the insertion of a 
trapping cassette (L1L2_Bact_P) in Gse1 gene using homologous recombination 
strategy. This allele in its basic state is coded Gse1tm1a and it includes beta-
galactosidase (LacZ) cassette with a polyA tail downstream from Engrailed 2 splice 
acceptor (EN2SA) and an internal ribosome entry site (IRES) mediating the initiation 
of LacZ protein translation with controlled expression by Gse1 promoter. After that, 
there is the coding sequence for neomycin resistance driven by the human beta-actin 
autologous promoter (hβactP) with another polyA tail, which are separated from the 
whole EN2SA-IRES-LacZ cassette by a LoxP site. All this sequence is flanked by two 
FRT sites, and followed by two other LoxP sites flanking the targeted exon (the third 
exon in the isoform Gse1-002) (Figure 2.1). This design is supposed to knockout 
Gse1 gene on transcription level due to the presence of the previously described 
trapping cassette, and the generated protein should be truncated including only the 
first 85 amino acids of the wild type protein translated from the longest isoform Gse1-
002. Several quality control tests had been performed on the ES cells by the 
providing company including 5’ end long-range PCR, 3’ end long-range PCR, LoxP 
sites confirmation, karyotyping and Southern blot. All information about this allele can 
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Figure 2.1: The design of the mutated allele Gse1tm1a(EUCOMM)Wtsi (Adapted and 
modified from: http://www.knockoutmouse.org/martsearch/project/71610).    
  This design, as described before, enables also the pre-conditional allele Gse1tm1a to 
be converted to the conditional allele Gse1tm1c by FLP-recombinase. That will remove 
the whole cassette except for the last two LoxP sites, which can be used later to 
convert it by Cre-recombinase to the null allele without the targeted exon Gse1tm1d. 
Direct breeding with Cre mice is also an option as mentioned before, producing a null 
allele tagged with LacZ protein by removing the cassette of neomycin resistance and 
the flanked exon in the optimal case, which is named as Gse1tm1b allele. However, 
other possibilities can happen, as only the targeted exon alone or the cassette of 
neomycin resistance alone may be removed, generating in this case the undesired 
alleles Gse1tm1b.1 or Gse1tm1b.2 respectively, which are not consistent with the goals of 
the knockout mouse project phase 2 (KOMP2) (Ryder et al. 2014). Rosa-FLP-e mice 
expressing FLP-recombinase that were used in this study were kindly given by Prof. 
Dr. André Fischer (UMG). Mice breeding and all other investigation were performed 
according to the standards of the Institutional Animal Care and Use Committee of the 
University of Göttingen. 
2.1.2 Chemicals 
  Table 2.1: List of the chemicals used in this study in alphabetical order with the 
providing supplier and the ordering number.   
Name Provider Ordering number 
20X LumiGLO and 20X Peroxide Cell Signaling 7003 
2-Mercaptoethanol ROTH 4227.3 
Acetic acid solution MERCK 1.37035.2500 
Agarose gel Biozym 840004 
Aniline blue solution Sigma-Aldrich HT154-250ML 
Bouin's solution Sigma-Aldrich HT10132-1L 
Chloroform Sigma-Aldrich C2432-500ML 
Collagenase II Worthington LS004176 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D8418-50ML 




Name Provider Ordering number 
dNTP Mix 10 Mm Invitrogen 18427-013 
EDTA 25 Mm Invitrogen y02353 
Ethanol ROTH 9065.2 
Fast SYBR green  
Master Mix 
Applied Biosystems 4385612 
Fetal calf serum Sigma-Aldrich F4135-500ML 
Formaldehyde ROTH P087.3 
Fuchsin solution Sigma-Aldrich HT151-250ML 
Glycin MERCK 1.04201.0100 
Isoflurane Abbvie B506 
Isopropanol ROTH 6752.2 
Lipofectamine 2000 Invitrogen 11668-019 
Magnesium Chloride Solution  
25 mM 
Sigma-Aldrich M8787-1.5ML 
Nuclease-Free Water QIAGEN 129114 
Oligo (dT) 12-18 Primers Invitrogen 18418-012 
Penicillin/Streptomycin solution Sigma-Aldrich P4333-100ML 
Phosphomolybdic acid solution Sigma-Aldrich HT153-250ML 
Phosphotungstic acid solution Sigma-Aldrich HT152-250ML 
Powdered milk ROTH T145.2 
Random Hexamers 50 µM Invitrogen N8080127 
TaqMan GTXpress  
Master Mix 
Applied Biosystems 4403311 
TGF-β1 R&D Systems 240-B-010/CF 
Trizol Ambion 15596-026 
Trypsin-EDTA 0.25% Sigma-Aldrich T4049-100ML 
Tween 20 ROTH 9127.2 
Weigert's iron hematoxylin 
solution 
Sigma-Aldrich HT107-500ML 





2.1.3 Commercial kits 
  Table 2.2: List of the commercial kits used in this in alphabetical order study with the 
providing supplier and the ordering number. 
Kit Provider Ordering number 
DNeasy Blood & Tissue Kit QIAGEN 69506 
Phusion High-Fidelity PCR Kit NEB E0553L 
PierceTM BCA Protein Assay Kit Thermo SCIENTIFIC 23225 
PureLinkTM RNA Mini Kit Ambion 12183025 
QIAquick Gel Extraction Kit QIAGEN 28706 
 
2.1.4 Cell culture mediums 
  Table 2.3: List of the cell culture mediums used in this study in alphabetical order 
with the providing supplier and the ordering number. 
Medium Provider Ordering number 
DMEM Gibco 41965-039 
Endothelial Cell Basic Medium Genlantis PM210500 
HCAEC Growth Medium Genlantis PM212500 
OPTI-MEM I (1X) Gibco 31985-062 
 
2.1.5 Buffers 
  Table 2.4: List of the buffers used in this study in alphabetical order with the 
providing supplier and the ordering number. 
Buffer Provider Ordering number 
NP-40 lysis buffer Invitrogen FNN0021 
NuPAGE LDS Sample  
Buffer (4X) 
Novex NP0007 




Buffer Provider Ordering number 
Phosphate buffered saline (PBS)  
for cell culture 
Gibco 14190-094 
Pierce Fast Semi-Dry Transfer 
Buffer 
Thermo SCIENTIFIC 35035 
TAE buffer 10X ROTH T845.2 
 
2.1.6 Instruments 
  Table 2.5: List of the instruments used in this study with the providing supplier in 
alphabetical order according to the function. 
Function Instrument Provider 
Cell culture hood BIOWIZARD KOJAIR 
Centrifugation Centrifuge 5424R Eppendorf 
Centrifugation for cell 
culture 
ROTOFIX 32 A Hettich 
DNA and RNA 
Concentration 
Measurement 
NanoDrop 2000 Thermo Scientific 
DNA electrophoresis Owl Easycast B2 Thermo Scientific 
Gel imaging BioDocAnalyze Biometra 
Heating block Thermomixer comfort Eppendorf 
Incubator for cell culture InCu safe EWALD 
Microscope BX43 OLYMPUS 
PCR cyclers 
Veriti 96 Well Thermo Cycler 







Protein transferring Fastblot B44 Biometra 
Real-time PCR cycler 
StepOnePlus Real-Time PCR 
System 
Applied Biosystems 
Tissue disruption TissueLyser LT QIAGEN 





  Table 2.6: List of the antibodies used in this study with the providing supplier and 
the working dilution. 
Antibody Provider Ordering number Dilution 
Anti-Gse1 (rabbit) Sigma-Aldrich SAB2101244-50UG 1:2000 
Anti-Gse1 (rabbit) LifeSpan Biosciences LS-C178849 1:2000 
Anti-β-Actin (mouse) Sigma-Aldrich A2228-200UL 1:5000 
Anti-α-Tubulin (mouse) Sigma-Aldrich T5168-.2ML 1:5000 
Anti-Mouse (rabbit) Dako P0161 1:5000 
Anti-Rabbit (goat) Dako P0448 1:2500 
 
2.1.8 Primers 
  Table 2.7: List of the primers used in this study for genotyping PCR and reverse 






55°C Gse1-Crit-WTR GTGGATCGGCCATATTGAGT 
Tm1a-5mut-R GAACTTCGGAATAGGAACTTCG 
Tm1c-EN2-R TGTTAGTCCCAACCCCTTCC 55°C 
Gse1-F GGCCCTGGTAGTCATGTGAA 60°C 
Gse1-ttR CTCCAGACTCCATTGACGGT 60°C 
Gse1-R GGAAGGGAAGCTCTATGGGG 60°C 
CSD-neoF GGGATCTCATGCTGGAGTTCTTCG 60°C 
CSD-lacF GCTACCATTACCAGTTGGTCTGGTGTC 60°C 
CSD-loxF GAGATGGCGCAACGCAATTAATG 60°C 



















m.linearRNA-R CCATTGACGGTTTTAGTGGGG 55°C 
 
  Table 2.8: List of the primers used in this study for quantitative real-time polymerase 
chain reaction (qRT-PCR) with the sequence and the product size. The annealing 
temperature was 60°C for all primers. 










h. α-SMA-F AAGCACAGAGCAAAAGAGGAAT 
76 bp 









































































2.1.9 Other materials 
  Table 2.9: List of the materials used in this study and not included in previous tables 
in alphabetical order with the providing supplier and the ordering number. 
Material Provider Ordering number 
100bp DNA ladder PROMEGA G210A 
1kb DNA ladder PROMEGA G571A 
Ad-Cre-IRES-GFP adenovirus Vector Biolabs 1710 
DNA loading dye 6X PROMEGA G190A 
DNase I Invitrogen 18068-015 
Eukaryotic 18S rRNA  
Endogenous Control 
Applied Biosystems 4310893E 
GSE1 Trilencer-27  
Human siRNA 
Origene SR308085 
Human Coronary Artery 
Endothelial Cells (HCAEC) 
Genlantis PH30005A 
Nitrocellulose blotting membrane Amersham 10600003 
NuPAGE 4-12% Bis-Tris 
Protein Gel 
Novex NP0335BOX 
Protein standards Invitrogen LC5800 
RNase R Epicentre RNR07250 
RNaseOUT™ Invitrogen 10777-019 






Material Provider Ordering number 
SuperScript™ III Reverse 
Transcriptase 
Invitrogen 18080-044 




2.2.1 Genomic DNA extraction 
  Genomic DNA was extracted from the tail of newborn mice obtained 4 weeks after 
birth, or from cultured cells using DNeasy Blood & Tissue Kit according to the 
manufacturer instructions. In details, the tissue sample was incubated with tissue 
lysis buffer and proteinase K at 56°C with shaking overnight or until it was completely 
lysed, or in the case of cultured cells proteinase K alone with PBS buffer were used 
without incubation, then lysis buffer was added and mixed thoroughly by vortexing. 
After that, 100 % ethanol was added and mixed, then the whole mixture was pipetted 
into the spin column, which was centrifuged for one minute then the flow-through was 
discarded. After two washing steps the precipitated DNA was eluted using AE elution 
buffer into new micro-centrifuge tube. The DNA concentration and quality were 
verified after that using NanoDrop 2000 machine, and the samples were stored for 
further experiments in 4°C fridge. 
2.2.2 RNA extraction 
  RNA was extracted from tissue samples or cultured cells using PureLinkTM RNA 
Mini Kit according to the manufacturer instructions. In details, after an initial 
homogenizing step in the case of tissue samples using the TissueLyser LT machine 
in 30Hz for 5 minutes, tissue samples or cultured cells were incubated with one ml of 
Trizol for 5 minutes at room temperature, then chloroform was added and the tube 
was shacked vigorously for 15 seconds. After three minutes of incubation at room 
temperature, the mixture was centrifuged for 15 minutes at 4ºC and the aqueous 
phase that contains the RNA was transferred into another tube. After that, ethanol 




The sample was then transferred to the spin cartridge and centrifuged for 15 seconds 
and the flow-through was discarded. After three times of washing and one 
centrifugation step for one minute to dry the membrane, the spin cartridge was 
transferred into a recovery tube and the RNA was eluted by adding 30–50 μl of 
nuclease-free water and incubating the tube in room temperature for one minute 
followed by centrifuging for two minutes. After measuring the concentration and 
verifying the RNA quality by NanoDrop 2000 machine, the sample was kept on ice to 
be used for further experiments or stored in -80°C fridge. All steps were performed 
using disposable RNase-free pipette tips and micro-centrifuge tubes. The embryonic 
RNA samples, which were extracted from the left lower limb of E15.5 embryos, were 
kindly given by Eva Baier, who is currently working on Gse1 project to investigate the 
timepoint and the reason of the observed lethality during embryonic development.    
2.2.3 RNA reverse transcription 
  Before cDNA synthesis, RNA samples were treated by 1 μl of DNase I with 1 μl of 
10X reaction buffer in 10 μl reaction volume at room temperature for 15 minutes to 
remove any contamination with genomic DNA, then the reaction was stopped by 
adding 1 μl of EDTA 25 mM and heating the sample to 65°C for 10 minutes. After 
that, 200-1000 ng RNA according to the sample concentration were reverse-
transcriped by adding 1 μl of oligo (dT) primers and 1 μl of dNTP Mix and incubating 
the mixtures for 5 minutes at 65°C. Then after chilling the sample on ice for at least 
one minute, 4 μl of 5X First-Strand Buffer, 2 μl of DTT and 1 μl of RNaseOUT™ were 
added and mixed gently and incubated for two minutes at 42°C. After that 1 μl of 
SuperScript™ II Reverse Transcriptase was added and the sample was incubated at 
42°C for 50 minutes, then for 15 minutes at 70°C to stop the reaction.  
  For circular RNA experiments SuperScript™ III Reverse Transcriptase was used 
according to the manufacturer instructions, with random hexamers, oligo (dT) primers 
or both of them as described in the results section (Jeck et al. 2013; Salzman et al. 
2012). All cDNA samples were diluted in 1:10 ratio before using them in further 
experiments, and they were stored in -20°C fridge. 
2.2.4 RNase R treatment 
  Regarding circular RNA, the RNA sample was treated in some experiments with 




which were incubated with 3 Unit/μg of RNase R and 5 μl of 10X reaction buffer in 
total reaction volume of 50 μl at 37°C for three hours, then the RNA was recovered 
using Trizol and PureLinkTM RNA Mini Kit as described above. Another sample was 
prepareded with the same steps but without RNase R (0 Unit/μg of RNase R) as a 
control for the whole procedure, then 200 ng of RNA for each sample were used for 
cDNA synthesis and further experiments (Starke et al. 2015). 
2.2.5 DNA extraction from agarose gel 
  DNA was extracted from agarose gel using QIAquick Gel Extraction Kit according to 
the manufacturer instructions. In details, where indicated in the results sections, the 
gel slice containing the PCR product of interest was cut and incubated with suitable 
volume of buffer QG at 50°C until the gel was dissolved, then isopropanol was added 
to the sample and mixed. The mixture was loaded onto a spin column and 
centrifuged for one minute with discarding the flow-through. After that, washing with 
buffer QG then with buffer PE followed by one centrifugation step to get rid of the 
residual ethanol were performed, then the DNA was eluted by nuclease-free water 
into a new collection tube. Suitable amount of the extracted DNA depending on the 
size of the PCR product (18 ng per 100 bases) was used for sequencing after mixing 
it with 3 μl of sequencing primer diluted in 10 pmol/μl aliquots in total reaction volume 
of 15 μl according to the suggested protocol by the sequencing laboratory (Seqlab-
Göttingen, http://www.seqlab.de/index.php?id=93). The sequencing results were 
analyzed using the program ApE- A plasmid Editor V2.0.47.  
2.2.6 Genotyping PCR 
  To genotype our ‘Knockout-first’ mice a set of three primers was used. The first 
primer was Gse1-5arm-WTF which is located in the 5’ homology arm and can give a 
PCR product of 241 bp from the wild type allele when used with the second primer, 
Gse1-Crit-WTR (WT PCR1), which is located in the region before the critical exon. 
The mutated allele Gse1tm1a cannot give a product using those two primers due to the 
insertion of the trapping cassette, which makes the product too big to be amplified in 
the conditions used in the genotyping PCR. The third primer, Tm1a-5mut-R, is 
universal mutant-specific reverse primer that is located in the sequence just after the 
5’ homology arm before the first FRT site, and can give with the primer Gse1-5arm-




Gse1tm1c (Mutant PCR1) (Figure 2.2). The PCR was performed in 25 μl reaction 
volume using 50-100 ng of genomic DNA, 1 μl of each one of the three primers after 
diluting them in 10 pmol/μl aliquots, 2.5 μl of Magnesium Chloride Solution, 2.5 μl of 
10X PCR buffer without Mgcl2, 0.5 μl of DMSO, 1 μl of dNTP Mix and 0.3 μl of Taq 
DNA Polymerase. The PCR conditions were as follows: 1. 95ºC 10 min, 2. 95ºC 15 
sec, 3. 55ºC 30 sec, 4. 72ºC 30 sec, 5. Steps 2,3, and 4 repeated for 35 cycles, 6. 
72ºC 7 min, 7. Hold at 4 ºC. After that, samples were mixed with 5 μl of DNA loading 
dye 6X, then 15 μl of the mixture were loaded with 100bp DNA ladder on 2.5% 
agarose gel prepared in TAE buffer 1X, and left to run for 15 minutes at 80 volt then 
one hour at 120 volt. After that the gel was imaged to determine the genotype and 
the images were documented. 
   
 
     
     
 
 
Figure 2.2: The genotyping protocols for Gse1 gene and the quality control tests 
used in this study (Adapted and modified from Ryder et al. 2013).     
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To genotype the newborn mice after breeding between the ‘Knockout-first’ mice and 
mice expressing FLP-recombinase, the same three previous primers were used. In 
this case, the primers Gse1-5arm-WTF and Gse1-Crit-WTR will give an amplicon 
from the allele Gse1tm1c but with the size 427 bp, which is larger than the product 
from the wild type allele due to the presence of the remaining FRT and LoxP sites. 
Additionally, another primer, the Tm1c-EN2-R, which is located in En2SA sequence, 
was used in separated PCR reaction with the primer Gse1-5arm-WTF applying the 
same conditions (tm1c PCR). This reaction will not give a product from the allele 
Gse1tm1c because the trapping cassette is deleted, but it will give a 231 bp product 
from the mutant allele Gse1tm1a (Figure 2.2). Another pair of primers was also used to 
detect the cassette coding for FLP-recombinase, which were FLP-Geno-F and FLP-
Geno-R primers. These primers are supposed to give an amplicon of 139 bp if the 
cassette is inside the genomic DNA of the mouse. This PCR reaction was also 
performed separately using the same PCR conditions described above. 
  The genotyping was also confirmed using second protocol with 5 primers: the 
primers Gse1-F and Gse1-ttR that are located in the 5’ homology arm and in the 
targeted exon respectively, and can give a PCR product of 796 bp from the wild type 
allele or a larger product of 982 bp from the allele Gse1tm1c (WT PCR2); the universal 
mutant-specific primer CSD-neoF, which is located in the cassette of neomycin 
resistance and can give with the primer Gse1-ttR a product of 1074 bp from the 
mutant allele Gse1tm1a only, but not from the wild type allele or the mutant allele 
Gse1tm1c (Mutant PCR2); the universal mutant-specific primer CSD-loxF and the 
primer Gse1-R, which are located in the region of the third LoxP site and in the 3’ 
homology arm respectively and can give a product of 1003 bp from both mutant 
alleles Gse1tm1a and Gse1tm1c, but not from the wild type allele (Mutant PCR3). The 
PCR steps were as described before for the first protocol except that three PCR 
reactions were performed separately, and the annealing temperature was 60ºC with 
one minute as extension time, which is also not enough to get an amplicon from the 
mutant allele Gse1tm1a using the primers Gse1-F and Gse1-ttR, and the samples 
were loaded after that on 1.5% agarose gel with a suitable DNA ladder. 
2.2.7 Short-range PCR 
  To confirm the structure of our trapping cassette, several short-range PCR reactions 




used: the primers 5FRT_F and 5FRT_R for the 5’ end of the cassette that should 
give an amplicon of 204 bp; the primers LacZ_2_small_F and LacZ_2_small_R for 
the LacZ cassette that should give an amplicon of 108 bp; and the primers 
Floxed_PNF and Floxed_LR for the region of 3’ LoxP that should give an amplicon of 
1078 bp (Figure 2.2) (Ryder et al. 2013). These 3 PCR reactions were performed 
separately applying the PCR conditions and the following steps as in the first 
genotyping protocol for the first two pairs of primers, and as in the second genotyping 
protocol for the third pair. The annealing temperatures for these reactions are 
described in the primers list. 
2.2.8 Long-range PCR 
  This PCR was performed to prove that our gene is correctly targeted (Figure 2.2) 
(Ryder et al. 2013). In order to do that a primer specific for Gse1 located after the 3’ 
homologous region, the primer Gse1-GR, was used with universal mutant-specific 
primer, CSD-loxF, and these two primers are supposed to give a product of 4363 bp 
when the trapping cassette is in the right position. The reaction was performed using 
Phusion High-Fidelity PCR Kit with applying the following protocol. 200 ng of genomic 
DNA, 2.5 μl of each one of the two primers after diluting them in 10 pmol/μl aliquots, 
10 μl of 5X Phusion GC Buffer, 2.5 μl of DMSO, 1 μl of dNTP Mix and 0.5 μl of 
Phusion DNA Polymerase were mixed in 50 μl reaction volume. Phusion Polymerase 
was added at last to prevent primer degradation caused by its 3´→ 5´exonuclease 
activity, and then the mixture was rabidly incubated in a pre-heated thermocycler to 
the denaturation temperature. The PCR conditions were as follows: 1. 98ºC 3 min, 2. 
98ºC 15 sec, 3. 68ºC 30 sec, 4. 72ºC 4 min, 5. Steps 2,3, and 4 repeated for 35 
cycles, 6. 72ºC 10 min, 7. Hold at 4 ºC. After that, 10 μl of DNA loading dye 6X were 
added to each sample and mixed, then 30 μl of the mixture were loaded on 0.8% 
agarose gel with 1kb DNA ladder.  
2.2.9 Reverse transcription PCR 
  Reverse transcription PCR (RT-PCR) was performed in some experiments to prove 
the circularity of the RNA detected by the primers m.circularRNA-F and 
m.circularRNA-R, which are supposed to give an amplicon with the size of 117 bp. 
After cDNA synthesis by SuperScript™ III Reverse Transcriptase, 2 μl of the diluted 




pmol/μl aliquots, 2.5 μl of Magnesium Chloride Solution, 2.5 μl of PCR buffer without 
MgCl2 10X, 1 μl of dNTP Mix and 0.3 μl of Taq DNA Polymerase. The PCR 
conditions were as follows: 1. 95ºC 3 min, 2. 95ºC 15 sec, 3. 55ºC 30 sec, 4. 72ºC 20 
sec, 5. Steps 2,3, and 4 repeated for 45 cycles, 6. 72ºC 7 min, 7. Hold at 4 ºC, and 
the PCR products were loaded with 100bp DNA ladder on 2.5% agarose gel.  
2.2.10 Quantitive real-time PCR 
  After diluting the cDNA in 1:10 ratio, 5 μl were used for each reaction, mixed with 10 
μl of SYBR Green Master Mix, 1 μl of the forward primer and similar amount of the 
reverse primer after diluting them in 4 pmol/μl aliquots in total volume of 20 μl per 
reaction. The fast protocol with the following PCR conditions was used: 1. 95ºC 20 
sec, 2. 95ºC 3 sec, 3. 60ºC 30 sec, 4. Steps 2 and 3 repeated for 40 cycles. Melting 
curve was added at the end of the PCR reaction to ensure the specificity of the 
primers. The results were analyzed using ΔΔCт method, where the expression of the 
gene of interest in the tested samples was normalized to another housekeeping gene 
(GAPDH) and then compared with one control sample. 
  For the wild type break point loss of allele (BP- LOA) assay, which was performed in 
order to confirm the correct position of the trapping cassette in our gene, qRT-PCR 
with TaqMan probe was used (Figure 2.2) (Ryder et al. 2013). This experiment 
depends on the fact that some loss in the genomic DNA of the targeted gene will 
happen due to the insertion of the trapping cassette, and the sequence of this 
deleted region will not exist in the mutated allele, provided that the desired gene is 
correctly targeted, and the probe is designed to span this lost sequence. In each 
reaction for this assay 100 ng of genomic DNA were used with 5 μl of TaqMan 
master mix, 0.4 μl of the FAM-labeled probe diluted in 5 μM concentration, 0.9 μl of 
the forward primer and 0.9 μl of the reverse primer after diluting them into 10 pmol/μl 
aliquots in total reaction volume of 10 μl. Dot1L gene was used as internal control. 
The results were analyzed using ΔΔCт method as described before, and the PCR 
conditions were as follows using the standard protocol: 1. 50ºC 2 min, 2. 95ºC 10 
min, 3. 95ºC 15 sec, 4. 60ºC 60 sec, 5. Steps 3 and 4 repeated for 45 cycles. 
  For analyzing the expression of Gse1 circular RNA, TaqMan probe covering the 
junction between the beginning and the end of the circularized exon was used (Jeck 




mix, 0.5 μl of the FAM-labeled probe for the circular RNA diluted in 5 μM 
concentration, 0.5 μl of VIC-labeled probe together with primers for 18S ribosomal 
RNA as housekeeping gene, 1 μl of the forward primer (m.circularRNA-F) and 1 μl of 
the reverse primer (m.circularRNA-R) after diluting them into 10 pmol/μl aliquots in 
total reaction volume of 10 μl. The PCR conditions were the same as for the (BP- 
LOA) assay, and the results were analyzed using ΔΔCт method. 
2.2.11 Isolation of mouse fibroblasts 
  Mouse fibroblasts were isolated from adult mouse kidneys using the following 
protocol: isoflurane anesthesia then cervical dislocation were performed to the adult 
mice then kidneys were isolated (among other organs such as heart, lung and liver, 
which were used for other experiments) and washed well with PBS. After that they 
were cut into very small pieces that can pass easily through 10-ml cell culture pipet 
tip then were incubated with 3-5 ml of Collagenase II (diluted to the concentration of 5 
mg/ml in PBS) for 15 minutes at 37°C with repeated mixing every three minutes. 
After that they were centrifuged for 5 minutes using 1000 rpm velocity and the 
supernatant was discarded. Then after one step of washing with PBS and discarding 
the supernatant by centrifuging, they were incubated with three ml of Trypsin for 5 
minutes at 37°C. After that the trypsin was neutralized by similar amount of complete 
growth medium supplemented with 20% fetal calf serum (FCS). After centrifugation, 
the supernatant was discarded and the pellet was suspended in 5 ml of complete 
growth medium and cultured in 10-cm dish in the cell culture incubator, then the 
medium was changed in the next day and every two days thereafter. 
2.2.12 Cell culture 
  HCAEC cells were cultured in T75 flasks or 10-cm dishes using 10 or 6 ml of 
HCAEC Growth Medium respectively, which was supplemented with 1% 
Penicillin/Streptomycin and changed every two days, and the cells were incubated at 
37°C with 5% CO2 in a humidified incubator. The cells were passaged every 5-7 
days in 1:2 ratio. That was done by washing with phosphate buffered saline (PBS) for 
cell culture then incubating with 4 ml of trypsin at 37°C for 2-3 minutes, then the 
trypsin was neutralized by equivalent amount of growth medium and collected in 15-
ml falcon tube and centrifuged for 5 minutes at 1300 rpm. After that, the supernatant 




divided into the two new flasks. All the experiments in this study were performed 
using HCAEC cells of early passages (passage 3-6). Primary mouse fibroblasts were 
cultured in DMEM medium supplemented with 20% fetal calf serum and 4% 
Penicillin/Streptomycin and passaged every 4-5 days in 1:3 ratio. 
2.2.13 EndMT assay 
  To induce EndMT in HCAEC, an established protocol in our lab was used (Xu et al. 
2015a). In this protocol TGF-β1 was used, which is described in previous studies to 
be able to activate EndMT in endothelial cells (Moonen et al. 2010; Zeisberg et al. 
2007b). 1.2 x 105 cells were cultured in one well of 6-well plate using HCAEC Growth 
Medium, and in the next day the medium was changed into Endothelial Cell Basic 
Medium to starve the cells. After 24 hours, the medium was changed again into 
HCAEC Growth Medium diluted in Endothelial Cell Basic Medium in 1:10 ratio, and 
10 ng/mL of TGF-β1 was added. The treatment was repeated every two days. Cells 
incubated in the same medium without TGF-β1 were used as a control. Samples 
were collected for RNA isolation after 2 and 6 days. RNA samples from mouse 
cardiac endothelial cells (MCEC) were kindly given by Elisa Sanchez Sendin, who 
established the protocol of EndMT assay for this cell line in our lab.     
2.2.14 Small interfering RNA transfection 
  HCAEC were transfected with small interfering RNA against KIAA0182 using 
Lipofectamine 2000 according to the manufacturer protocol. 1.5 x 105 cells were 
cultured in one well of 6-well plate 24 hours before the transfection using HCAEC 
growth medium without antibiotics. In the next day 50 pmol of each of the three 
provided small interfering RNAs (siRNAs) were diluted together in 250 μl of OPTI-
MEM medium. Three μl of Lipofectamine 2000 were also diluted in 250 μl of OPTI-
MEM medium and mixed well, then after 5 minutes of incubation in room temperature 
both previous dilutions were combined together. During the following 20 minutes of 
incubation in room temperature the growth medium for the cells was changed into 
endothelial cell basic medium, then the Lipofectamine-siRNA-OPTI-MEM mixture 
was added to the cells and mixed gently. After 4 hours of incubation the medium was 
changed back into HCAEC growth medium then the cells were incubated again. 
Samples were collected for RNA isolation after 24, 48 or 72 hours. All previous steps 




KIAA0182-siRNA; different confluency of the cells and different incubation period with 
the Lipofectamine-siRNA-OPTI-MEM mixture to get the highest possible efficiency for 
the transfection with the lowest cell toxicity. Cells transfected with equivalent amount 
of scrambled siRNA were used as a control.  
2.2.15 Transduction of primary fibroblasts with Cre-recombinase adenovirus 
  In order to prove the conditionality of our ‘Knockout-first’ mice, 1 x 105 fibroblasts 
isolated from the kidneys of adult mice from different genotypes (wild type or 
heterozygous) were seeded in one well of 6-well plate using complete growth 
medium. In the next day after washing with DMEM medium without any serum, the 
cells were incubated in one ml of basic medium after adding of 5 μl of Ad-Cre-IRES-
GFP adenovirus achieving thereby a multiplicity of infection (MOI) of 500 according to 
the manufacturer instructions. After 24 hours the cells were washed with PBS and 
two ml of complete growth medium were added. The transduction efficiency was 
estimated in the next day depending on the signal of green fluorescent protein (GFP) 
in the transducted cells, and then genomic DNA was extracted from those cells as 
described above to be used in further experiments. 
2.2.16 Protein extraction 
  NP-40 lysis buffer was used to extract protein from tissue samples. TissueLyser LT 
machine was used for homogenizing then the tissue samples were incubated in 200-
400 μl of lysis buffer for 40 minutes on ice with vortexing every 10 minutes for 10 
seconds. After sonication for 1.5 minutes (15 seconds on alternatively with 15 
seconds off) the lysate was centrifuged for 10 minutes at 4°C, then the supernatant 
was collected and used for further experiments or stored in -80°C fridge. PierceTM 
BCA Protein Assay Kit was used to determine the concentration of the protein 
samples according to the manufacturer instruction. 
2.2.17 Western blotting 
  10-20 μg of each protein sample with equal volume of 2X sample buffer, which was 
prepared by mixing 2.5 ml of NuPAGE LDS Sample Buffer (4X) with 1.5 ml of water 
and one ml of 2-Mercaptoethanol, were loaded into the wells of NuPAGE 4-12% Bis-
Tris Protein Gel with protein standards after denaturation step at 95°C for 5 minutes 




for 75 minutes at 120 volt, and after that the proteins were transferred to 
nitrocellulose blotting membrane using Pierce Fast Semi-Dry Transfer Buffer diluted 
10 times in water. That was done by running in the transfer chamber for 15 minutes 
at 150 mA then for 45 minutes at 250 mA after confirming that no air bubbles were 
trapped. Afterwards, the membrane was blocked by incubating with 5% powdered 
milk diluted in PBST (PBS with 1% Tween 20) for one hour at room temperature then 
incubated with the primary antibody diluted in the blocking buffer at 4°C overnight. 
After three times of washing for 10 minutes each with 2% powdered milk in PBST, 
the membrane was incubated with HRP-linked secondary antibody diluted in the 
blocking buffer at room temperature for one hour then washed three times again with 
2% powdered milk in PBST and one time with PBS for 5 minutes. After that the 
membrane was developed by applying the chemiluminescent substrate (20X 
LumiGLO and 20X Peroxide in 1:1 ratio diluted to 1X in water) and imaged. When 
necessary, the membrane was stripped by incubating with Glycin (0.1 mM solution 
adjusted to PH=3) for 30 minutes at room temperature, then after washing for 5 
minutes with PBS it was blocked again and incubated with another primary antibody.    
2.2.18 Ascending aortic constriction (AAC) 
  This operation was used in several previous studies as a mouse model for pressure 
overload on left ventricle mimicking aortic stenosis (Jiang et al. 2007; Takahashi et al. 
2007; Zeisberg et al. 2007b). It is possible to make the constriction on different levels, 
such as the ascending, transverse or descending aorta, but the constriction of the 
ascending aorta is reported to cause significant and fast pressure overload on the left 
ventricle producing thereby a high degree of hypertrophy after 48 hours (Tarnavski et 
al. 2004). All the operations in our study were kindly performed by Julia Steinbrecher, 
and age-matched male animals were always operated. In short details, after the mice 
were anesthetized and ventilated, a left thoracotomy was performed then a ligation 
around the ascending aorta was applied using a silk suture and a 23-gauge blunted 
needle, then the needle was removed. In the case of sham operation, all steps were 
the same, except that no ligation was made. The gradient across the constriction site 
was measured two days after the operation, and detailed echocardiography for the 
operated mice was kindly performed by Marcel Zoremba, Roland Blume and Beate 
Knocke after 7 days. The animals were sacrificed two weeks after the operation by 




be used later for RNA and protein extraction, and after washing with PBS the hearts 
were fixed in 10% formaldehyde followed by paraffin embedding.     
2.2.19 Masson's trichrome staining 
  This staining method has been used in a lot of studies to quantify the fibrosis 
induced by different mechanisms in different organs, such as liver, kidney and heart, 
where the collagen fibers will be stained in blue color and the nuclei in black with red 
background (Amin and Mahmoud-Ghoneim 2011; Tampe et al. 2014; Xu et al. 
2015b). The established protocol for this staining in our lab was as follows: 
transverse sections with 3 μm thickness were prepared from the embedded hearts, 
then the sections were deparaffinized and rehydrated by immersing them two times 
in xylol for 10 minutes each, two times in 100% ethanol for 5 minutes each, one time 
for 5 minutes in 95% ethanol, one time for 5 minutes in 80% ethanol, one time for 5 
minutes in 50% ethanol and finally one time for 5 minutes in 30% ethanol. After 
washing in distilled water, the samples were immersed in Bouin's solution, which was 
prewarmed to 56°C, for 15 minutes. After that, they were left to cool down in normal 
water for 5 minutes, and then washed using running tap water for 5-10 minutes until 
the yellow color was removed. Immersion in Weigert's iron hematoxylin solution for 5 
minutes followed, then washing again by running tap water for 5 minutes. After that, 
three times of washing in distilled water were done, followed by immersion in acid 
Fuchsin solution for 5 minutes then three times of washing with distilled water were 
repeated. The sections after that were immersed in phosphomolybdic-
phosphotungstic solution (prepared by mixing one volume of both acids with two 
volumes of water) for 5 minutes, followed by 10 minutes of immersion in Aniline blue 
solution. Then the sections were rinsed for very short time once in acetic acid 
solution, once in distilled water, twice in 96% ethanol, twice in 100% ethanol and at 
the end twice in xylol for 5 minutes each. After that, the sections were covered by 
cover slips and left to dry overnight. The fibrosis was quantified microscopically using 
CellSens Dimension 1.6 computer program, where the ratio of fibrosis was defined as 
the fibrotic area / the area of the myocardium in the left ventricle.    
2.2.20 Statistical analysis 
  Statistical analysis and figures production were performed using GraphPad Prism 6 




deviation in the genotyping results from the expected Mendelian ratio. For the results 
of qRT-PCR and the characteristics and results of the mice objected to AAC and 
sham operation one-way analysis of variance (one-way ANOVA) followed by post 
hoc analysis with Bonferroni correction was used when more than 2 different groups 
of animals were included (Takahashi et al. 2007; Xu et al. 2015b). Otherwise, two-
tailed one-sample t-test, was used to compare the results of the tested samples with 
a hypothetical mean of 1 or 100% in the wild type animals or the control group of 
cells as shown in each figure (Ewald et al. 2015; Ge et al. 2011). The cutpoint of p-
value less than 0.05 was used to determine whether the difference was statistically 
significant. In all comparisons at least 3 age- and sex-matched animals from each 




















3.1 Genotyping protocols for ‘Knockout-first’ mice 
  As described previously, 2 independent protocols were used to genotype our 
‘Knockout-first’ mice. In the first one we used 3 primers: Gse1-5arm-WTF, Gse1-Crit-
WTR and Tm1a-5mut-R, which give one product of 241 bp in the mice that have 2 
Gse1 wild type alleles (Gse1WT/WT), and these mice are named as wild type mice 
thereafter in our study. In the mice that have 2 Gse1tm1a(EUCOMM)Wtsi mutated alleles 
(Gse1tm1a/tm1a), one amplicon of 127 bp is amplified, and these mice are named in our 
study as homozygous mice. The third genotype is found in the mice that have one 
mutated and one wild type allele (Gse1tm1a/WT), and these mice will give both products 
using this genotyping PCR and are named in our study as heterozygous mice (Figure 
3.1). In the genotyping PCR one additional sample was included serving as a 
negative control, in which nuclease-free water was used instead of genomic DNA and 
should give none of the products. In the second protocol we used 5 primers in 3 
separated reactions: Gse1-F and Gse1-ttR together; CSD-neoF and Gse1-ttR 
together; and CSD-loxF and Gse1-R together. Three products are to be obtained in 
the heterozygous mice with the sizes 796, 1074 and 1003 bp respectively. Only one 
amplicon from the first pair in the wild type animals, or 2 products from the last 2 
pairs in the homozygous mice should be detected (Figure 3.1). 
 
Figure 3.1: The genotyping protocols used in our study. Left: In the heterozygous 
mice 2 bands were detected using the primers Gse1-5arm-WTF, Gse1-Crit-WTR and 
Tm1a-5mut-R, but only one band of the large or small size is detected in the wild type 
or the homozygous mice respectively. Right: In the second protocol 3 PCR reactions 
were performed. One band from the primers Gse1-F and Gse1-ttR (upper lane); or 




CSD-loxF and Gse1-R (lower lane) were obtained in the wild type or the homozygous 
mice respectively. All three bands were detected in the reactions of heterozygous 
mice. 
 
3.2      Quality control tests 
  The ES cells used to generate our mice were tested in several ways by the supplier, 
but it was found by Ryder and his colleagues that more than 10% of mice generated 
from ES cells with similar design to ours had problems related to incorrect targeting 
of the gene of interest or deletion of the 5’ end of the trapping cassette (Ryder et al. 
2013). Therefore, we performed several quality control tests on the heterozygous 
mice from the first generation (G1) contributing to expand our colony to exclude these 
problems. 
3.2.1 Confirming the specificity of  Gse1 targeting  
  As described in the methods section, long-range PCR was performed to prove that 
the trapping cassette was correctly inserted in Gse1 gene. Positive band with the 
right size was detected after PCR performed with samples from G1 heterozygous 
animals, but not with samples from a wild type mouse or with the negative control 




          
   limits of 3’ homology arm              exon                         critical exon                FRT site                LoxP site 
CSD-loxF          Long-range PCR      Gse1-GR                     




Figure 3.2: Upper: Schematic representation of the long-range PCR showing the 
locations of the primers Gse1-GR and CSD-loxF, which were also used to sequence 
the PCR product. Lower: The results of long-range PCR using these primers, 
showing that a positive band was detected with the size of more than 4 kb from the 
tested G1 heterozygous animals, but not in the reactions of the wild type animal or 
the negative control using nuclease-free water.   
          
 
                *         *         *         *         *         *         *         *         *         * 
 17901 AGGTGAGCTTGATACGCACCCGGTACTGGAAGATGCTAGGATTAAGAGATGGCGCAACGCAATTAATGATAACTTCGTATAGCATACATTATACGAAGTT 18000  
                                                                                                      |||||        
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~AAGTT 5      
                                           
                                                               
  
                *         *         *         *         *         *         *         *         *         * 
 18001 ATGGTCTGAGCTCGCCATCAGTTCAATCAGACTTGTGACAGAGTACCACAAATTCATCGTTGCTTGCTTTAGGAGGCCAGAGCCTCCCTAAGCCTGGGGA 18100  
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
     6 ATGGTCTGAGCTCGCCATCAGTTCAATCAGACTTGTGACAGAGTACCACAAATTCATCGTTGCTTGCTTTAGGAGGCCAGAGCCTCCCTAAGCCTGGGGA 105    
                *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
 18101 GGGAGGGGGTCGCCAAGGCCCTGCCCCTTTACACAGTGGTGTCTTATTGTGTCCTCTGGTGGCCTGGACGGCAATCACTTCTTTAGGGGTCTACATACCC 18200  
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   106 GGGAGGGGGTCGCCAAGGCCCTGCCCCTTTACACAGTGGTGTCTTATTGTGTCCTCTGGTGGCCTGGACGGCAATCACTTCTTTAGGGGTCTACATACCC 205    
           *         *         *         *         *         *         *         *         *         *      
   
                *         *         *         *         *         *         *         *         *         * 
 18201 AGAGGCACCAGGTTGAGACAGACAACAACCATAGAGTGCCTTGGATCTTTGGCTAGACAATAGCTGTGACTGCTTTGGAGGAGTAGGGGCGGGACTGTAG 18300  
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||#|||||||        
   206 AGAGGCACCAGGTTGAGACAGACAACAACCATAGAGTGCCTTGGATCTTTGGCTAGACAATAGCTGTGACTGCTTTGGAGGAGTAGGGGCGGNACTGTAG 305    
           *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
 18301 GCTAACTCTGATGGTCCCTGATGCCAGCCAGCACCGGGGTCCTTGTGTCTGCAGTCTCTAGCTGGCCATAACCTAACTGCAGTGGAGGAGCCAGCCCCAG 18400  
       |||||||||||||||||||||||||||||||#|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||#        
   306 GCTAACTCTGATGGTCCCTGATGCCAGCCAGNACCGGGGTCCTTGTGTCTGCAGTCTCTAGCTGGCCATAACCTAACTGCAGTGGAGGAGCCAGCCCCAN 405    
           *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
 18401 AGCTTCCCCTGTACTGCTGGGCCTCCCGGCGGCCTGGCAGCCTGGCGCCTAGAGGGGGCCTTGCTAATTAAGAACCGCTGTCAGCTGTGGCTTTCCCGGG 18500  
       ||||||||||||||||                                                                                            
   406 AGCTTCCCCTGTACTG~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 421    
           *         * 
 
                *         *         *         *         *         *         *         *         *         * 
257101 CCATTAGTCTCAGTGGCCTGATCTGCCCTGAGGTCCTTGGCCCCATCTGACCTTGTGGTCCAGCCTTTGTTGAGACAGACTTATCAGGTGTCCTAAACAC  
               
   220 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 220    
 
                *         *         *         *         *         *         *         *         *         * 
257201 ATTTAAGCCCATCCTCTGGGTCTGGGGAACAGAGAGCCCCTCCAGCATCTCTATCCACTCGTGGGGACCTTGAGGGACAGGCAGCTTCCCATCTGTGCAG  
               
   220 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 220    
 
                *         *         *         *         *         *         *         *         *         * 
257301 TCTGGGCTTCATGCCAGGCTGTACCTCACTGAGAGGCAGGACCTGAGCCTGGTGAGGGAGTGTGGCACATTACCTCTGCTCCCCACTTCCCCCTCCCACA  
               
   220 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 220    
 
                *         *         *         *         *         *         *         *         *         * 
257401 GCCTCCAGCGGCCTGTGCACCATGTGGTGCCCCCCAGCACGGTGACTGAGGACTACTTGAGAAGCTTCCGGCCCTACCACACTGCTGAAGACTTACGCAT  
               
   220 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 220    
 
                *         *         *         *         *         *         *         *         *         * 
257501 GTCCTCCTTGCCTCCGCTTGGCCTGGACCCAGCCACCGCCGCAGCCTACTATCACCCCAGCTACCTGGCCCCACACCCATTCCCCCACCCGGCCTTCAGG  
                          |||#|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   220 ~~~~~~~~~~~~~~~~~~~GGCNTGGACCCAGCCACCGCCGCAGCCTACTATCACCCCAGCTACCTGGCCCCACACCCATTCCCCCACCCGGCCTTCAGG 140    
                          *         *         *         *         *         *         *         *         * 
  
                *         *         *         *         *         *         *         *         *         * 
257601 TGAGGCGTCCCCACTCACGCTGCCCTGTGTGCTAATCTGTTCTCAGCAAGGCAGAACCTCTCGGGGCGGGCGTTTGCCAGGGCTTGGGGTCCAGGCACTC  
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   139 TGAGGCGTCCCCACTCACGCTGCCCTGTGTGCTAATCTGTTCTCAGCAAGGCAGAACCTCTCGGGGCGGGCGTTTGCCAGGGCTTGGGGTCCAGGCACTC 40     
                *         *         *         *         *         *         *         *         *         * 
 
                *         *         *         *         *         *         *         *         *         * 
257701 AAGGGAGCTATATAGCTTTCCCCAGCTCGACTGAGTTGAGTCTTGATGGATGGACTCAGTACCACCTGCTGATGCTCCTTGGTTCCCACTTCTCAGCATC  
       |||||||||||||||||||||||||||||||||||||||        
    39 AAGGGAGCTATATAGCTTTCCCCAGCTCGACTGAGTTGA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
                *         *         * 
 
                *         *         *         *         *         *         *         *         *         * 
257801 TGCACCCCAGCAGCCAGTCCCCACTAACAGTGTGTGGTACCTAGACAGTGTGATGGAGACTCCGGAGTGAGAGTCAGGCCATGCCCTCCCTCTTCCTGTA  
                                                                                                                  




Figure 3.3: Upper: Alignment between the first sequencing result of the amplicon 
from long-range PCR (lower sequence) obtained by CSD-loxF primer (sequence in 
blue), and the vector PG00193_Z_8_B01 with the trapping cassette L1L2_Bact_P 
that was used to generate the mutated allele Gse1tm1a(EUCOMM)Wtsi (upper sequence) 
(https://www.i-dcc.org/imits/targ_rep/alleles/2232/targeting-vector-genbank-file). 
Lower: Alignment between the reverse complement of the second sequencing result 
of the same amplicon (lower sequence), obtained by Gse1-GR primer (sequence in 
yellow) and Gse1 genomic DNA (upper sequence) 
(http://www.ensembl.org/Mus_musculus/Gene/Sequence?db=core;g=ENSMUSG000
00031822;r=8:120230536-120581390). Sequence in green indicates the 3’ 
homologous arm.  
  Another experiment was also performed to confirm Gse1 targeting, which was qRT-
PCR with TaqMan probe detecting the break sequence in Gse1 wild type allele (the 
deleted region from the genomic DNA of Gse1 due to the insertion of the trapping 
cassette), which is named as break point loss of allele (BP- LOA) assay. It was 
proven that this break region cannot be detected in the samples from homozygous 
animals, and it was also shown that this sequence was found almost two times more 
in the wild type animals compared with the heterozygous, as they have two wild type 
alleles compared with one in the heterozygous mice (Figure 3.4).   
 
Figure 3.4: The results of (BP- LOA) assay. Mean value and standard error for each 
animal were normalized to the first heterozygous animal and represented. The same 
amount of genomic DNA that includes the break sequence of the wild type allele 
(regarded as one copy of this allele) was detected in the tested G1 heterozygous 
animals numbers 1, 01, 03, 010 and 030, which were involved in expanding our mice 
colony. Similar amount of genomic DNA including the break sequence was found in 
the heterozygous embryo number 171-E3. The double amount was found in the wild 
type animals (the adult mice number 75 and 87 and the embryo number 171-E5), and 
this sequence was not detected at all in homozygous animals (the embryos number 
171-E2, 171-E7 and 107-E1).  




3.2.2 Confirming the structure of the trapping cassette 
  Several short-range PCRs were performed to confirm that no part of our trapping 
cassette is missing using different pairs of primers detecting the 5’ end, the LacZ 
cassette and the region of 3’ LoxP, which were 5FRT_F and 5FRT_R; 
LacZ_2_small_F and LacZ_2_small_R; Floxed_PNF and Floxed_LR respectively. All 
tested samples from G1 heterozygous mice showed the expected amplicon from all 
these PCRs indicating that the trapping cassette was complete (Figure 3.5). In 
addition to that, the PCR using the primers CSD-neoF and Gse1-ttR was performed 
during genotyping for all G1 heterozygous mice and other animals proving that the 
cassette of neomycin resistance was also not deleted.  
 
Figure 3.5: The results of short-range PCRs using the primers 5FRT_F and 5FRT_R 
(upper lane); the primers LacZ_2_small_F and LacZ_2_small_R (middle lane) and 
the primers Floxed_PNF and Floxed_LR (lower lane), indicating that none of the 
following regions in the trapping cassette; the 5’end, the LacZ cassette and the 
region of 3’ LoxP was missing respectively, confirming thereby the structure integrity 
of this cassette in all tested heterozygous mice from the first generation.    
 
3.3      Genotyping results 
   Genotyping was performed for the newborn mice from breeding between 
heterozygous male and heterozygous female using the two protocols mentioned 
above. Interestingly, out of more than 130 newborn mice from more than 20 litters 
and different males and females in breeding, no homozygous newborn mouse was 
observed (Table 3.1). The heterozygous animals accounted for 62% of all the 




were wild type mice representing significant deviation from the Mendelian ratio 1:2:1 
with p-value less than 0.0001, and indicating clearly that the homozygousity of Gse1 
trapping is lethal. 52% of the animals were males with no significant deviation from 
the ratio 1:1 (p-value = 0.6042). No lethality in the heterozygous mice could be 
proven as there were no significant deviation from the expected ratio 2:1 of the 
surviving heterozygous and wild type newborn mice (p-value = 0.2458). The average 












M F M F M F 
03 & 01 3 3 3 8 3 0 0 17 
35 & 42 4 8 5 11 6 0 0 30 
35 & 49 2 2 4 3 5 0 0 14 
030 & 64 1 4 0 0 0 0 0 4 
030 & 55 1 0 1 2 2 0 0 5 
85 & 81 1 1 1 2 1 0 0 5 
85 & 82 1 2 1 1 2 0 0 6 
80 & 74 4 3 6 6 7 0 0 22 
80 & 71 2 3 0 2 5 0 0 10 
176 & 150 1 1 0 1 3 0 0 5 
147 & 182 1 0 2 1 2 0 0 5 
164 & 219 1 1 0 1 2 0 0 4 
215 & 192 1 0 0 4 3 0 0 7 
Total 23 28 23 42 41 0 0 134 
 
Table 3.1: The genotyping results of the newborn mice from 23 different litters of 13 
matings between heterozygous male and heterozygous female, showing that no 
homozygous newborn mouse was found.  
  Representative results of genotyping PCR for 20 mice chosen from 5 different litters 
are shown in figure 3.6, where we see that the DNA samples of all genotyped 
animals produced a positive band from the primers Gse1-5arm-WTF and Gse1-Crit-
WTR, meaning that all these animals had at least one wild type allele. This band was 




provided the same results (except for very few cases related mostly to bad quality of 
the DNA sample, which required repeating the PCR using more DNA or applying 
higher numbers of cycles or with a new sample of genomic DNA). The sequencing 
results of the band from the primers Gse1-F and Gse1-ttR, which was also positive in 
all tested animals, were also specific for Gse1 gene.  
 




                *         *         *         *         *         *         *         *         *         * 
252601 ATGTGTCCGCAGGTAGCATGATTGTCCCGGGAAAGAGGGGGCTATGTTAGTGACAGAGACCATCCCTCACTACCAAGTTCTGTTGGAACCGACACTCCCA  
                                                                   ||||||||||||||||||||||||||||||||||||||||        
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~CATCCCTCACTACCAAGTTCTGTTGGAACCGACACTCCCA 40     
                                                                            *         *         *         * 
 
                *         *         *         *         *         *         *         *         *         * 
252701 AGAACTAAGCTGCCTCACTACCGCCACCTACCTGCCCCTCTTCCCTTTTGCTGCTGGGGGTGGTTGGCAAGGGAAACACATTGCTTCTTTCTGGGGTCGT  
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
    41 AGAACTAAGCTGCCTCACTACCGCCACCTACCTGCCCCTCTTCCCTTTTGCTGCTGGGGGTGGTTGGCAAGGGAAACACATTGCTTCTTTCTGGGGTCGT 140    
                *         *         *         *         *         *         *         *         *         * 
 
                *         *         *         *         *         *         *         *         *         * 
252801 GAGGCTGTTCTGGGTATAGTAGCATTCACTCAATATGGCCGATCCACCGGAGGTACATTGACGTGGTTTTAAAAGAGTGAGTGACATCTCAGATTTTTTA  
       |||||||||||||||||||||||||||||||||||||||||||||||                                                            
   141 GAGGCTGTTCTGGGTATAGTAGCATTCACTCAATATGGCCGATCCAC~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 187    
 
 
Figure 3.6: Upper: The genotyping results of 20 newborn mice from breeding 
between heterozygous male and heterozygous female, using the primers Gse1-
5arm-WTF, Gse1-Crit-WTR and Tm1a-5mut-R. None of them was homozygous, as 
all of them gave positive band from the primers Gse1-5arm-WTF and Gse1-Crit-WTR 
(the upper band). Lower: Alignment between Gse1 genomic DNA (upper sequence) 
(http://www.ensembl.org/Mus_musculus/Gene/Sequence?db=core;g=ENSMUSG000
00031822;r=8:120230536-120581390) and the sequencing result of the positive 
band from the primers Gse1-5arm-WTF (sequence in blue) and Gse1-Crit-WTR 
(sequence in yellow), which was obtained using the primer Gse1-5arm-WTF for 
sequencing (lower sequence). 
  The genotyping results of the newborn mice when one of the parents was wild type 
and the other one was heterozygous showed that 57% of them were heterozygous 
with no significant deviation from the Mendelian ratio 1:1 (p-value = 0.1253), 
indicating also that the lethality does not affect the heterozygous mice (Table 3.2). 
46% of the newborn animals were males with no significant deviation from the ratio 














M F M F 
030  &  A4 2 5 4 5 3 17 
030  &  A3 1 2 0 2 2 6 
40  &  A11 1 1 2 6 0 9 
43  &  A13 2 3 3 3 6 15 
39  &  A12 3 4 4 4 11 23 
197  &  231 1 1 3 1 3 8 
A8  &  64 6 7 7 6 9 29 
A7  &  1 1 0 1 1 1 3 
A9  &  010 1 2 0 0 1 3 
233  &  229 2 2 2 2 4 10 
Total 20 27 26 30 40 123 
 
Table 3.2: The genotyping results of the newborn mice from 20 different litters of 10 
matings between heterozygous male and wild type female or the opposite, showing 
that no lethality can be proved in the heterozygous animals.  
 
3.4      Generating mice with Gse1tm1c allele 
  In accordance with the aims of the knockout mouse project phase 2 (KOMP2), 
several matings between heterozygous mice and mice expressing FLP-recombinase 
were arranged. However, when the newborn mice were positive for FLP-recombinase 
and heterozygous for Gse1, the mutated allele Gse1tm1a was not converted 
completely to Gse1tm1c. It was shown according to our genotyping results that both 
types of mutated allele were present in the same mouse, which means that we had 
mosaic mice, where the mutated allele Gse1tm1a were converted to the mutated allele 
Gse1tm1c in some cells but not in the others. Those results were confirmed several 
times by both genotyping protocols in different litters from the first generation after 
breeding with FLP-recombinase mice. The genotyping result of the first litter in this 






        
                     
Figure 3.7: The genotyping results of the newborn mice from the mating between a 
heterozygous male (Gse1tm1a/WT) and a FLP-positive female, showing that we had 
mosaic mice (number 5 and 8). Three bands were detected using the primers Gse1-
5arm-WTF, Gse1-Crit-WTR and Tm1a-5mut-R (first lane); and two bands using the 
primers Gse1-F with Gse1-ttR (third lane). The bands with the larger size from both 
reactions (427 bp and 982 bp respectively) indicated that we had the mutated allele 
Gse1tm1c, as this allele will produce larger amplicon compared with the wild type allele 
due to the remaining FRT and LoxP sites. However, an amplicon was still detected 
using the primers Gse1-5arm-WTF with Tm1c-EN2-R (second lane), and the primers 
CSD-neoF with Gse1-ttR (4th lane), which should be negative if the trapping cassette 
is completely removed by FLP-recombinase. The 5th lane is the PCR results using 
the primers CSD-loxP and Gse1-R, which give positive band from both mutant alleles 
(Gse1tm1a and Gse1tm1c).  The 6th lane is the PCR results using the primers FLP-
Geno-F and FLP-Geno-R, which give positive band when FLP-recombinase cassette 
is inside the genomic DNA of the mouse. Our genotyping protocols are described in 
details in the methods section (Paragraph 2.2.6, Figure 2.2)  
  After that these mosaic mice were bred with wild type mice, and we were able to 
identify using our genotyping protocols several heterozygous animals with pure 
mutant Gse1tm1c allele among the newborn mice, such as number 116 and 120 in 
figure 3.8. These results were also confirmed by other primers, such as 
LacZ_2_small_F and LacZ_2_small_R primers. Some of these mice were negative 












generate the mice with the mutant allele Gse1tm1d in order to confirm the causative 
relationship between the observed lethality and the trapping of Gse1. 
 
             
Figure 3.8: The genotyping results of newborn animals from breeding between one of 
the previously described mosaic mice and wild type mouse, showing that we had 
heterozygous mice with pure Gse1tm1c allele (number 116 and 120). No amplicon was 
detected using the primers Gse1-5arm-WTF and Tm1c-EN2-R (second lane), the 
primers CSD-neoF and Gse1-ttR (4th lane) or the primers LacZ_2_small_F and 
LacZ_2_small_R (7th lane) from these two animals. The PCR results using the 
primers Gse1-5arm-WTF, Gse1-Crit-WTR and Tm1a-5mut-R; the primers Gse1-F 
and Gse1-ttR; the primers CSD-loxP and Gse1-R and the primers FLP-Geno-F and 
FLP-Geno-R are shown in the first, third, 5th and 6th lane respectively. 
 
3.5      Generating  Gse1tm1b allele in vitro 
  Our mice were already tested to confirm the presence of the LoxP sites, which allow 
them to work as a conditional mouse model, but we wanted to confirm that in vitro 
before breeding with Cre-recombinase mice. Therefore, fibroblasts from the kidneys 
of wild type and heterozygous mice were isolated and transducted by Cre-
recombinase virus, which is supposed to convert the mutant allele Gse1tm1a to 
Gse1tm1b allele. We were able to achieve a transduction efficiency of 70% as 























      
 
 
Figure 3.9: Kidney fibroblasts from heterozygous and wild type animals transducted 
with adenovirus expressing Cre-recombinase, showing a transduction efficiency of 
70% percent approximately in both groups of cells according to how many cells are 
GFP-positive.     
  Afterwards, genomic DNA was isolated from those cells and the triple-PCR-
reactions of the second protocol were performed as described before. Additionally, 
one PCR was performed using Gse1-R primer with the primer CSD-lacF, which is 
located in the LacZ cassette. This reaction is supposed to give an amplicon of 1301 
bp if we have the mutated allele Gse1tm1b, in which the cassette of neomycin 
resistance and the targeted exon should be removed by Cre-recombinase. However, 
in case of the allele Gse1tm1a the PCR product will be more than 4 kb, which is not 
possible to be amplified because of our PCR conditions. The results are shown in 
figure 3.10 suggesting that we obtained the desired Gse1tm1b allele but not in all cells, 
as we were still able to detect a positive band, but weaker one, from the reactions 



















That reflected likely the genomic DNA extracted from the cells, where the 
transduction with Cre-recombinase virus was not successful.  
   
Figure 3.10: The genotyping results of the transducted fibroblasts, showing that we 
had cells with the allele Gse1tm1b, indicated by the positive band from the PCR using 
the primers Gse1-R and CSD-lacF (4th lane). The PCR results using the primers 
Gse1-F and Gse1-ttR; the primers CSD-neoF and Gse1-ttR; and the primers CSD-
loxP and Gse1-R are shown in the first, second and third lane respectively. 
 
3.6      Gse1 expression results 
  To prove the connection between the lethality in the homozygous mice and the 
trapping of Gse1, RNA samples from embryonic tissue were analyzed by qRT-PCR 
after reverse transcription. The primers, m.Gse1-F and m.Gse1-R, are located after 
the trapping cassette in exon 6 and 7 from the isoform Gse1-002 respectively. That 
should enable us to detect the difference in the expression level among mice of 
different genotypes. Western blotting was also performed using embryonic protein 
samples. It was found that Gse1 expression was significantly lower in the 
homozygous embryos compared with the wild type, but the mRNA and the protein of 
Gse1 were still detected in these mice (with expression level of more than 50 % 




results of LacZ reporter, which showed clear upregulation in the heterozygous and 
homozygous, suggested that the trapping cassette is working (Figure 3.12), and it 
can be concluded that the trapping system generated a hypomorphic allele of Gse1 
instead of null allele.  
 
Figure 3.11: Left: The expression level of Gse1 in samples from wild type, 
heterozygous and homozygous embryos, represented by means and standard errors, 
where (*) indicates p-value less than 0.05. Right: Western blotting showing minimal 
difference among the three genotypes using two different antibodies for GSE1 protein 
(Sigma-Aldrich in the upper lane and LifeSpan Biosciences in the middle) against two 





Figure 3.12: The expression level of LacZ in samples from wild type, heterozygous 
and homozygous embryos, represented by means and standard errors, where (***) 









  The expression level of Gse1 was also tested in adult mice by qRT-PCR and 
Western blot, which showed that the highest expression is in the lung and liver 
among the tested organs, and suggested that different protein isoforms are 
expressed in these organs (Figure 3.13). It was also found, that the heterozygous 
adult mice have significantly lower Gse1 expression in heart and kidney, but not in 
lung and liver, compared with the wild type (Figure 3.14).  
 
Figure 3.13: Left: The expression level of Gse1 in samples from different organs of 
adult mice estimated by qRT-PCR and represented by means and standard errors. 
Right: Western blotting of protein samples from different organs of adult mouse using 
antibody for GSE1 protein (Sigma-Aldrich) in the upper lane and antibody against α-








Figure 3.14: The expression level of Gse1 in heart, kidney, liver and lung using 
samples from heterozygous adult mice compared with wild type littermates and 
represented by means and standard errors. 
 
3.7      Gse1 circular RNA results 
  Our gene is described to produce circular RNA from the second exon of the isoform 
Gse1-002 (Memczak et al. 2013), which is located on genomic level just upstream 
from the intron, in which the trapping cassette was inserted. Therefore, it could be 
possible that the splicing process that controls the expression of this circular RNA is 
affected, and in this case that may be involved in the observed lethality of the 
homozygous mice. To test our hypothesis we started by proving that Gse1 circular 
RNA is expressed during embryonic development. We designed 2 outward-facing 
primers, m.circularRNA-F and m.circularRNA-R, and performed RT-PCR with cDNA 
synthesized from embryonic RNA samples using either random hexamers, oligo (dT), 
or both of them for reverse transcription (Jeck et al. 2013; Starke et al. 2015). As it is 
shown in figure 3.15, we were able to obtain an amplicon, and only from the samples 
prepared using random hexamers, which indicates that we were detecting non-
polyadynelated RNA. The band was extracted from the gel and proved by 
sequencing that it belongs to the exon we are looking for, but in scrambled form 
(Figure 3.16). Another PCR using primers for mouse Gapdh was performed for the 





                                 
Figure 3.15: The RT-PCR results using embryonic RNA after reverse transcription 
with random hexamers, oligo (dT), or both of them, showing that we had the amplicon 
of the scrambled exon from the outward-facing primers, m.circularRNA-F and 
117 bp  




m.circularRNA-R, only in samples reverse transcriped by random hexamers (upper 
lane). That reflects the absence of polyA tail in the detected RNA, which is a criterion 
for its circularity. The RT-PCR using mouse Gapdh primers (lower lane) was 
performed as a control, which is supposed to give an amplicon of 123 bp.  
 
 
                       *         *         *         *         *         *         *         *         *      
       1 ~~~~~GCATGAGCCATGAGCCCAAGTCCCCTTCCATAGGGATGCTTTCCACGGCGACCAGGACCACCGCCACCGTCAACCCCCTCACCCCCTCGCCACTC 95     
              ||||||||||||||||||||||||||||||||||||||||||||||||||||                                                    
       1 CAGAGGCATGAGCCATGAGCCCAAGTCCCCTTCCATAGGGATGCTTTCCACGGCGAC~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 56     
                  *         *         *         *         * 
 
             *         *         *         *         *         *         *         *         *         *      
      96 AATGGCGCCCTGGTGCCCACCGGTAGCCCGGCCACCAGCAGTACGCTGTCGGCCCAGGCCGCTCCATCCTCCAGCTTTGCTGCCGCACTGCGCAAGCTCG 195    
                                                                                                                  
      56 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 56     
 
             *         * 
     196 CCAAACAGGCAGAGGAGCCCAGAG 219    
                                      







                  *         *         *         *         *         *         *         *         *         * 
       1 GCATGAGCCATGAGCCCAAGTCCCCTTCCATAGGGATGCTTTCCACGGCGACCAGGACCACCGCCACCGTCAACCCCCTCACCCCCTCGCCACTCAATGG 100    
                                                                                                                  
      71 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 71     
 
                  *         *         *         *         *         *         *         *         *         * 
     101 CGCCCTGGTGCCCACCGGTAGCCCGGCCACCAGCAGTACGCTGTCGGCCCAGGCCGCTCCATCCTCCAGCTTTGCTGCCGCACTGCGCAAGCTCGCCAAA 200    
                                                               ||||||||||||||||||||||||||||||||||||||||||||||        
      71 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~CGCTCCATCCTCCAGCTTTGCTGCCGCACTGCGCAAGCTCGCCAAA 26     
                                                             *         *         *         *         *     
 
                  * 
     201 CAGGCAGAGGAGCCCAGAG~~~~~~ 219    
         |||||||||||||||||||              
      25 CAGGCAGAGGAGCCCAGAGGCATGA 1      
              *         * 
 
Figure 3.16: Upper: Alignment between the sequencing result of the product from the 
primers m.circularRNA-F (sequence in blue) and m.circularRNA-R (sequence in 
yellow), which was obtained using the primer m.circularRNA-F (lower sequence), and 
the sequence of the circularized exon of Gse1 (upper sequence) 
(http://www.ensembl.org/Mus_musculus/Gene/Sequence?db=core;g=ENSMUSG000
00031822;r=8:120230536-120581390). The alignment between the sequences in 
green at the beginning of the sequencing result and at the end of the circularized 
exon proves the scrambled junction between the beginning and the end of the exon. 
Lower: Alignment between the reverse complement of the sequencing result for the 
same product obtained by the primer m.circularRNA-R (lower sequence) and the 
sequence of the circularized exon of Gse1 (upper sequence). The alignment between 
the sequences in green confirms further the scrambled junction of this exon. 
  Afterwards, another experiment was performed to confirm further the circularity of 
the scrambled exon. RNA sample from wild type embryo was treated by RNase R 
before reverse transcription, which is supposed to digest the linear RNAs only. 
Another sample was prepared using the same conditions but without adding the 
RNase R to be used as a control. To prove that the digestion actually worked another 
PCR was performed for both samples as a control using the primer m.circularRNA-F, 




the next exon, which was m.linearRNA-R. These primers are supposed to give an 
amplicon of 240 bp, detecting thereby the linear RNA isoforms of Gse1 that contain 
the same circularized exon (Starke et al. 2015). According to our results the linear 
RNA isoforms were almost completely depleted in the sample treated with RNase R, 
but the amplicon from the primers that detect the scrambled exon was not affected, 




                                               
Figure 3.17: The RT-PCR results using embryonic RNA after treating with RNase R 
and reverse transcription using random hexamers and oligo (dT), showing that we 
still can get the amplicon of the scrambled exon using the outward-facing primers, 
m.circularRNA-F and m.circularRNA-R, in the sample treated with RNase R (upper 
lane). That indicates the resistance of the detected RNA to RNase R, which is 
another criterion for its circularity. The amplicon generated by the primers 
m.circularRNA-F and m.linearRNA-R that detect the linear RNAs of Gse1 was almost 
completely absent in the RNase R-treated sample, indicating the efficiency of the 
treatment (lower lane). Sample prepared using the same steps but without RNase R 
was used as a control. 
  After that, we used the same outward-facing primers mentioned above to quantify 
the expression level of the circular RNA of Gse1. QRT-PCR with TaqMan probe 
detecting the junction between the end and the beginning of the scrambled exon was 
performed to investigate the expression in embryos from different genotypes. 
According to our results, the expression of the circular RNA was significantly 
upregulated in the homozygous animals compared with the wild type (Figure 3.18), 
indicating that the trapping cassette, which is located after the circularized exon, 
caused more circular RNA and less linear RNAs of Gse1 to be generated. We are 
aware of the possibility that the primers we used to detect the linear isoforms may 
detect other circular RNA isoforms for Gse1 gene, but these isoforms are not 
described previously in the literature. 
117 bp  












Figure 3.18: The expression level of the circular RNA of Gse1 in samples from wild 
type, heterozygous and homozygous embryos, represented by means and standard 
errors, showing significant upregulation in the homozygous embryos compared with 
the wild type.    
  The expression of the circular RNA of Gse1 was also analyzed in different tissues 
from adult mice, and the highest expression was also found in the lung, but the 
lowest expression among the tested organs was in the liver (Figure 3.19).   
 
Figure 3.19: The expression level of Gse1 circular RNA in samples from different 
organs of adult mice estimated by qRT-PCR and represented by means and 
standard errors. 
  As the most well-described function of circular RNA is to work as miRNA sponge 
(Lasda and Parker 2014), we searched for the miRNAs, which can be sequestered 
by the circularized exon of Gse1 using its sequence as a query in the database for 
miRNAs (miRBase) (http://www.mirbase.org/search.shtml). Several candidate 






miR-3113-3p, mmu-miR-224-3p, mmu-miR-5110, mmu-miR-1947-3p, mmu-miR-
6930-3p, mmu-miR-7235-5p, mmu-miR-3081-5p, mmu-miR-6392-5p, mmu-miR-
6968-5p and mmu-miR-7215-3p. The miRNA mmu-miR-6968-5p was chosen from 
the predicted list, as it showed the best alignment in its seed region, and then we 
tried to search for the genes that could be targeted by this miRNA. More than 100 
genes were found to be potential targets according to the online database, miRDB 
(http://mirdb.org/miRDB/). The expression level of the 6 genes at the top of the list 
according to their targeting score was investigated in embryonic RNA samples from 
homozygous embryos, where the circular RNA was proved to be upregulated, in 
comparison with wild type littermates. These genes were Foxp4, Thy1, Actn4, Wnt1, 
Kmt2d and Tfap2b. Only one of these genes, Tfap2b, showed upregulation trend, 
with almost significantly higher expression in the homozygous embryos compared 
with the wild type (p-value = 0.059). This can support the hypothesis about possible 
role for the circular RNA of Gse1 as miRNA sponge, as its expression was increased 
in the homozygous embryos and should cause the suspected genes as miRNA 
targets to be upregulated by protecting them from the supposed inhibiting effect of 
this sequestered miRNA. Another gene, Thy1, was found to be significantly 
downregulated in the homozygous embryos, and the gene Actn4 showed 
downregulation trend (p-value = 0.072) (Figure 3.20). 
 
Figure 3.20: The expression level of Foxp4, Thy1, Actn4, Wnt1, Kmt2d and Tfap2b in 
samples from homozygous embryos compared with wild type littermates and 
represented by means and standard errors, showing significant downregulation in the 
expression of the gene Thy1, and upregulation and downregulation pattern in the 









3.8      The expression results of Gse1-neighboring genes 
  The mutated allele Gse1tm1a still includes the selection cassette of neomycin 
resistance with its autonomous promoter, making it possible that the observed 
lethality in the homozygous embryos was secondary to off-target effect of this 
promoter. To exclude this possibility, the expression level of several genes upstream 
and downstream from Gse1 on chromosome 8 was analyzed by qRT-PCR. Those 
genes were Usp10, Crispld2, Zdhhc7, Gins2, Cox4i1 and Irf8. None of the tested 
genes showed significant change in homozygous embryos compared with wild type 
(Figure 3.21). 
 
Figure 3.21: Upper: 1 Mb interval of chromosome 8 around Gse1 gene showing the 
candidate genes to be affected by the trapping cassette (Adapted from 
http://www.ensembl.org/Mus_musculus/Component/Location/Web/ViewTop/main?db
=core;g=ENSMUSG00000042269;r=8:120281341-
120292410;update_panel=1;export=png-5). Lower: The expression level of Usp10, 
Crispld2, Zdhhc7, Gins2, Cox4i1 and Irf8 in samples from homozygous embryos 









3.9      The role of KIAA0182 in EndMT  
  EndMT was found to be responsible for the formation of endocardial fibroelastosis, 
which is involved in the pathogenesis of HLHS. Therefore, we wanted to explore 
whether KIAA0182 has a role in EndMT process. First, we wanted to investigate how 
the expression of KIAA0182 will be changed by treating HCAEC cells with TGF-β1, 
which is already an established protocol to induce EndMT in our lab. Interestingly, it 
was found that KIAA0182 was progressively upregulated upon TGF-β1 treatment, 
which caused significant upregulation of EndMT markers SNAIL and SLUG (Figure 
3.22), indicating that this gene may be involved in mediating and/or regulating the 
response to TGF-β1 treatment in HCAEC cells. 
 
 
Figure 3.22: Upper: The expression level of KIAA0182 in human coronary arterial 
endothelial cells after treating them by TGF-β1 represented by means and standard 
errors, showing significant upregulation of KIAA0182 after 6 days of treatment 
compared with untreated cells. Lower: The expression level of EndMT markers 
SNAIL and SLUG in human coronary arterial endothelial cells after treating them by 








  These results were also reproduced in mouse endothelial cells, as it was found that 
TGF-β1 treatment in mouse cardiac endothelial cells (MCEC) to induce EndMT was 
associated with Gse1 overexpression (Figure 3.23)  
 
Figure 3.23: The expression level of Gse1 in mouse cardiac endothelial cells after 
treating them by TGF-β1 represented by means and standard errors, showing 
significant upregulation after 2 days of treatment compared with untreated cells.  
  After that, we tried to find out what the consequences of KIAA0182 downregulation 
will be, using HCAEC cells as in vitro model. Numerous trials were performed until we 
were successful in transfecting these cells by siRNA targeting KIAA0182 due to the 
difficulty of obtaining good transfection efficiency in endothelial cells. According to our 
results, we obtained the maximum downregulation 48 hours after the transfection. 
Surprisingly, that was followed directly in the next day by an increase in the 
expression of KIAA0182 to mildly higher levels compared with the cells transfected 










Figure 3.24: The expression level of KIAA0182 in human coronary arterial endothelial 
cells after transfecting them by KIAA0182-siRNA represented by means and 
standard errors, showing significant downregulation after one and two days.  
  We analyzed after that whether the downregulation of KIAA0182 was associated 
with any changes in the expression of EndMT markers, and it was found, that the 
transcription factor SNAIL only was slightly but significantly upregulated in the cells 
transfected by KIAA0182-siRNA. That was accompanied by upregulation of the 
mesenchymal marker α-SMA (Figure 3.25), which may represent spontaneous 
EndMT in HCAEC cells induced by the downregulation of KIAA0182, suggesting a 
potential function for this gene as a negative regulator of the EndMT process.   
     
Figure 3.25: The expression level of SNAIL and α-SMA in human coronary arterial 
endothelial cells 2 days after transfecting them by KIAA0182-siRNA represented by 
means and standard errors, showing significant upregulation compared with cells 
transfected by scrambled siRNA. 
 
3.10 Results of AAC operation 
  The homozygousity of the mutated allele Gse1tm1a was associated with mouse 
lethality during embryonic development, in spite of the fact that the mutated allele 
was only hypomorphic. The hearts of the heterozygous animals in our study showed 
small but significant downregulation in the expression of Gse1. Those mice in the 
Europhenome Mouse Project had a cardiac phenotype represented by heavier 
hearts, and in our mice colony it was found that the heart weight of the mice was 
mildly more in heterozygous males and females, but without significant difference 
compared with wild type animals (Figure 3.26). Therefore, we wanted to confirm our 






for cardiac fibrosis. Heterozygous and wild type age-matched male mice were 
subjected to AAC or sham surgery, using several echocardiographic parameters, 
representing the systolic function and cardiac hypertrophy of the left ventricle, and 
the degree of cardiac fibrosis after two weeks as endpoints for this experiment.  
 
Figure 3.26: The heart weight in heterozygous and wild type mice of both genders 
normalized to body weight and represented by means and standard errors. 
 The AAC operation was performed on 20 mice with 35% mortality during or directly 
after the operation, mostly because of bleeding, and the sham operation was 
performed on 11 animals with no operative mortality leaving 24 animals alive in total, 
creating 4 groups with 5-7 animals in each group. There was no statistically 
significant difference regarding the age of the mice among the 4 groups (Figure 
3.27). The pressure gradient across the constriction site was significantly higher in 
the groups of AAC operation compared with the groups of sham operation, but 
without any significant difference between the heterozygous group and the wild type 









Figure 3.27: The characteristics of the operated mice in this study represented by 
means and standard deviations, showing that the 4 groups were not significantly 
different regarding the age of the animals. The pressure gradient was as supposed 
significantly higher in both AAC groups compared with sham groups, but not 
significantly different between the heterozygous and wild type groups. 
  The echocardiography study for the mice one week after the operation showed that 
the heterozygous mice were not significantly different regarding the systolic function 
of the left ventricle after AAC operation and left ventricle hypertrophy, compared with 
the wild type mice. That was estimated depending on the ejection fraction and 
fractional shortening of the left ventricle; and the thickness of the anterior (AWT) and 
posterior wall (PWT) respectively (Figure 3.28). No difference was also detected 
regarding end-diastolic (LVEDD) and end-systolic dimensions (LVESD) of the left 
ventricle or the mass of the left ventricle normalized to the body weight of the animal. 
Similarly, the quantification of the fibrosis in the left ventricle did not show any 
statistically significant difference between the heterozygous and the wild type 
animals. 
 
Figure 3.28: The results of the AAC operation in this study, represented by means 
and standard deviations, showing that there was no significant difference between 
the heterozygous and wild type animals regarding all analyzed echocardiographic 
parameters of the left ventricle, and regarding the fibrosis ratio two weeks after the 







  The scientific basis of our study depends on the unpublished data that a de novo 
mutation in KIAA0182 gene was identified in HLHS, and it was not possible to be 
predicted whether it is a loss-of-function- or gain-of-function-mutation. However, the 
cardiac phenotype of small ventricle with large atrium in zebrafish model of KIAA0182 
knockout suggested a relevance of KIAA0182 knockout or downregulation in 
congenital heart diseases.    
  In this study we aimed to find a link between this gene and HLHS by utilizing the 
‘Knockout-first’ mice with the mutant allele Gse1tm1a(EUCOMM)Wtsi as in vivo model. 
These mice represent a useful biological tool to explore the phenotypes associated 
with inactivation of unknown genes, such as KIAA0182 or Gse1 in mouse, and to the 
best of our knowledge, this is the first study trying to answer this question using this 
model. Additionally, we tried to investigate the importance of this gene in EndMT 
process, which is described to be involved in the pathgenesis of HLHS. Our results 
indicated that the homozygousity of the allele Gse1tm1a(EUCOMM)Wtsi was clearly lethal. 
This muated allele behaved as a hypomorphic allele, not as a null allele as it is 
supposed to do. It was associated with upregulation of the circular RNA of Gse1 
gene, which may be functional as miRNA sponge, and might play a role in the 
observed lethality.   
  Before making any investigations using these mice, and in order to ensure the 
reliability of our results, it was important and time-worthy to exclude problems 
reported before in animals generated from ES cells with mutated allele of the same 
design as the allele Gse1tm1a. According to the study of Ryder and his colleagues, the 
targeting of wrong gene or the absence of the 5’end of the trapping cassette 
represented the most frequent reasons for the failure in the quality control tests 
applied to the mice (Ryder et al. 2013). It should be taken into consideration that the 
ES cells in that study were only tested by long-range PCR and sequencing before 
using them to produce the mice. However, the ES cell clone (EPD0557_2_C07), from 
which the mice in our study were generated, passed more detailed tests including 





  The quality control tests performed by us in this study included several short-range 
PCRs, detecting different parts of the trapping cassette. These parts were the 5’end, 
the LacZ cassette and the region of 3’ LoxP, in addition to the cassette of neomycin 
resistance which was confirmed through our genotyping protocols. According to our 
results, none of the previously mentioned parts was missing in the mutated allele, 
confirming the integrity of the trapping cassette. To exclude the possibility of wrong 
targeting, which was reported to be relatively common, we performed two 
experiments, which were break point loss of allele (BP-LOA) assay and long-range 
PCR. In the first experiment it was shown that all the tested heterozygous animals 
had the same number of copies of the wild type allele (approximately one copy) 
compared with two copies in the wild type animals and no copies in the homozygous 
embryos. That was determined according to qRT-PCR results using TaqMan probe, 
which detects the deleted region from Gse1 gene due to the insertion of the trapping 
cassette.  
  The second experiment was 3’ long-range PCR, where a product with the size of 
more than 4 kb was amplified from the heterozygous but not from the wild type 
animals, indicating the specificity of this PCR, which was also confirmed by the 
sequencing results of the amplicon. Another evidence for the correct targeting of 
Gse1 can also be extrapolated from the genotyping results, as we were able by two 
genotyping protocols for Gse1 gene to identify homozygous animals (during 
embryonic development only). This would not be possible if another gene was 
targeted and a product will always be amplified in that case by PCR detecting the 
wild type allele of the gene of interest (Gse1 gene in our study), as the trapping 
cassette is not inserted in this gene to interrupt the amplifying process (Ryder et al. 
2013).  
  After proving that Gse1 was for sure correctly targeted, our genotyping results 
showed that none of the genotyped newborn mice was homozygous, and these 
results were produced using two protocols without any contradictive events. It should 
be noticed that there are some redundancy in the results of the genotyping PCRs 
detecting the wild type allele in these two protocols. Both pairs of primers, Gse1-
5arm-WTF with Gse1-Crit-WTR in the first protocol and Gse1-F with Gse1-ttR in the 
second, are actually amplifying the same region of the wild type allele. Therefore, 




the required PCR conditions are fulfilled. These redundant results could have been 
avoided by using the (BP-LOA) assay as a genotyping modality, not only as a quality 
control test. This PCR can be used together with another qRT-PCR assay with 
TaqMan probe that detects the LacZ or the neomycin resistance cassettes to decide 
the copies number of the mutated allele. However, we cannot neglect in this case the 
economic burden of using such protocol to genotype each animal in the colony. 
Regarding the mutant allele, the problem of redundancy was avoided. The primers 
used to detect the mutant allele in the first protocol, Gse1-5arm-WTF and Tm1a-
5mut-R, are amplifying the 5’ end of the trapping cassette. The two pairs of primers 
used in the second protocol, Gse1-ttR with CSD-neoF and Gse1-R with CSD-loxF, 
are detecting different regions, which are the cassette of neomycin resistance and 
the 3’ LoxP site respectively. This indicates that all heterozygous genotyped mice, 
not only G1 heterozygous mice tested by the quality control PCRs, were proved to 
have these regions inside their genome. 
  In total, 134 animals born from several heterozygous with heterozygous matings 
were genotyped, and no homozygous newborn mice were found. According to that, it 
can be safely concluded that we observe embryonic lethality in the homozygous 
animals. It might also be suspected that unspecific product, which has the same size 
predicted to be obtained from the primers pairs in wild type reactions, was amplified, 
and this might be the reason why all the genotyped animals were found to have wild 
type allele. However, this is highly unlikely to happen for two pairs of primers, and the 
sequencing results of the product from both of them proved the specificity of our 
genotyping protocols, which represents one of the most important strengths in this 
study.  
  It can also be concluded that heterozygous animals are not affected by this lethality, 
as the numbers of the surviving mice are not significantly deviated from the expected 
ratio of 1:2 in previous matings, and no deviation from the ratio of 1:1 was found 
when matings were between heterozygous and wild type parents. Our results 
indicated also that both genders are involved in this phenotype, as the numbers of 
the surviving males and females are not significantly different, meaning that the 
lethality happened in similar numbers of animals from both genders. It should be kept 
in mind in this context that the genotyping was performed for the newborn mice 4 




animals died after birth during the time period before genotyping. However, it was 
clearly clarified with the responsible caretakers of the animals that each newborn 
mouse should be reported and genotyped. Actually, in three cases we were informed 
about weak animals, which did not seem to be able to survive after birth, and those 
animals were also genotyped and all of them were heterozygous.    
  Detailed investigations are currently undergoing to answer the questions regarding 
when, why, and how the homozygous animals died during embryonic development. 
However, one of the most essential questions also is whether the observed lethality 
can be caused by the incomplete knockout of Gse1 gene, which was detected 
according to our results. At the begining we should notice that the expression of 
different splicing variants in different organs can be predicted depending on our 
Western blot results. The antibody used in that experiment is against an epitope 
located in the second and third exon of the isoform Gse1-002 in mouse and human. 
It can be predicted that this polyclonal antibody detects also the isoforms Gse1-001, 
Gse1-003 and Gse1-006 in human; and the isoforms Gse1-001 and Gse1-003 in 
mouse, as these isoforms contain the previously mentioned exons, but not the other 
isoforms. Similarly, the primers that we have used for qRT-PCR in human and mouse 
show this limitation. Therefore, it should be always kept in mind by the interpretation 
of our present results that we may not be detecting all expressed isoforms of Gse1 
gene. Further efforts are certainly needed to establish primers that can determine the 
expression level of each isoform in specific way, because different isoforms can have 
different functions as described in previous studies for other genes (Castelli et al. 
2014; Heemskerk et al. 2011). 
  However, the primers m.Gse1-F and m.Gse1-R that we used to analyze the 
expression level of Gse1 in different genotypes are located in exon 6 and 7 from the 
isoform Gse1-002 respectively. The trapping cassette in the mutated allele 
Gse1tm1a(EUCOMM)Wtsi, which is based on the design of gene-trap vector, is inserted in 
the intron upstream from the third exon. That is supposed to produce truncated 
mRNA consisting of the first two exons and the LacZ reporter (Figure 4.1) (Skarnes 
et al. 2011; Stanford et al. 2001). Therefore, these pimers should be able to show the 
difference in the expression level due to the insertion of this trapping cassette, and 
we found that the expression of Gse1 in the RNA samples from the homozygous 




shown using samples extracted from the left limb of E15.5 embryos, and it was also 
confirmed on protein level by detecting GSE1 protein in the homozygous samples, 
meaning that the mutated allele behaved as a hypomorphic allele. The results in the 
heterozygous embryos showed that we have less than 20% downregulation effect. 
We tested also different organs from adult wild type mice, and they showed different 
expression level for Gse1. Additionally, the tested organs showed variable level of 
Gse1 trapping, as the difference in Gse1 expression between wild type and 
heterozygous animals was significant in heart and kidney, but not in lung and liver. 
This hypomorphic state was previously reported in different previous papers about 
gene trapping. When the trapping cassette is inserted in an intron, which is the case 
in our mutated allele, different splicing pattern can happen, making the trapping not 
completely efficient (Hanstein et al. 2013; Maguire et al. 2014; Stanford et al. 2001). 
However, as we found that Gse1 had different trapping efficiency in adult mice, this 
can also be the case in embryonic tissues. This dfference may be important in 
determining the reason of the lethality, which can be related to the organ with the 
most needed expression of Gse1 during certain stage of embryonic development.  
 
Figure 4.1: The design of gene-trap vector, consisting of a splice acceptor (SA) site 
and promoterless LacZ cassette followed by polyA tail, which is supposed to disrupt 
the expression of the targeted gene on mRNA and protein level (Adapted and 
modified from Stanford et al. 2001). 
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  In a recent study using transgenic mice with similar design to our mutated allele (the 
‘Knockout-first’ allele) for different gene, it was reported that the downregulation 
effect was relatively similar in different organs (around 65 % decrease in the 
expression level of the targeted gene in homozygous animals compared with wild 
type). However, it was more than the decrease measured using samples from the tail 
of the animals (around 50%). Careful inspection of the data presented in that study 
shows also that the trapping effect in the bladder was less than 55 %, which was 
clearly lower than the reported downregulation in the liver (more than 70 %) 
(Hanstein et al. 2013). Similar differences were also described in another study using 
the same trapping mechanism but without an independent promoter upstream from 
the sequence for neomycin resistance, but this difference was more clearly 
manifested in the heterozygous animals, as the homozygous mice showed more than 
95 % trapping effect in all tested tissues in that study (Chen et al. 2013).  
  All this argues for the possibility that trapping efficiency differs from tissue to tissue. 
Therefore, we cannot assume that the observed decrease in Gse1 expression, as it 
was estimated in the tested embryonic RNA from the animals limbs, necessarily 
reflects the trapping state in each tissue or cell type and at each timepoint of the 
embryonic life. The apparently inadequate trapping of Gse1 in the homozygous 
embryos does not absolutely mean that the lethality is not caused by Gse1 
downregulation, but may on the opposite suggest that the expression of Gse1 is so 
important temporarily or spatially for the embryo, that only less than 50 % decrease in 
this expression is enough to cause embryonic lethality. 
  On the other hand, we should not neglect the fact that the selection cassette with its 
promoter is still inside our mutated allele. Consequently, it is not usually 
recommended in this stage to consider that the generated phenotype is surely 
caused by the observed downregulation of Gse1 gene. In principle, it is possible that 
the observed lethality is due to off-target effect of this promoter, which may have 
bidirectional activity and can cause changes in the expression profile of one or more 
of the neighboring genes located more than 100 kb apart from the targeted gene 
(Johnson and Friedmann 1990, Pham et al. 1996; Ren et al. 2002; Ryder et al. 2014; 
Scacheri et al. 2001).  
  This undesired scenario was described in details in the paper of Maguire and his 




of that study. The researchers showed in their study that the homozygous animals 
with two mutated alleles of Slc25a21 gene (Slc25a21tm1a) had a phenotype 
comprising orofacial abnormalities, hearing defect and inflammation in the middle 
ear. However, in spite of the fact that the expression of Slc25a21 was more than 70 
% downregulated, the expected symptoms of 2-oxoadipate acidaemia were not found 
in these mice. In order to further investigate the mechanism behind these results, the 
mice were bred with transgenic mice expressing FLP- and Cre-recombinase. 
Surprisingly, the observed phenotype was not reproduced in the homozygous mice 
for the mutated allele Slc25a21tm1b or Slc25a21tm1d, although they had lower 
expression of the studied gene compared with the homozygous mice for the allele 
Slc25a21tm1a (almost 0 % and 13 % of the expression level in the wild type mice 
respectively). These findings suggested that the phenotype was caused by off-target 
effect of the selection cassette. In order to prove that, the expression level of several 
genes located within 1 Mb interval around Slc25a21 was investigated. Only one of 
these genes, Pax9, was found to be affected exclusively in the Slc25a21tm1a-
homozygous animals.  Pax9 downregulation was known before to cause similar 
phenotype in mice (Maguire et al. 2014).  
  The first conclusion from this study is that the magnitude of the trapping effect in the 
targeted gene, neither in the case when it seems adequately high nor when it is 
relatively low as we observed for Gse1, is enough as evidence for or against the 
causal relationship between the gene of interest and the observed phenotype. 
Second, it is not possible to predict exactly how the insertion of the trapping cassette 
will affect the splicing pattern of the targeted gene, either before or after breeding 
with Cre mice, and wide spectrum of trapping efficiency can be expected using the 
same design of trapping cassette. This may range from less than 50 % 
downregulation according to our results up to more than 95 % as shown in another 
publication (Nijnik et al. 2012).  
  Third, it may be necessary to analyze the expression level of the genes flanking 
Gse1 on chromosome 8 (Figure 3.21), and according to the results in our study, none 
of the tested neighboring genes was affected in the homozygous embryos. However, 
the detection of any mis-regulated gene will not be adequate to prove that it is 
caused by the presence of the selection cassette, as it can be simply a secondary 




neighboring genes is associated with a phenotype similar to the one reported in our 
study, this gene should be kept in mind as a possible target for this potential off-target 
effect. To the best of our knowledge, none of the genes shown in figure 3.21 is 
described before to cause embryonic lethality in mouse model 
(http://www.informatics.jax.org/). All this together argues more in favour of the 
conclusion that a direct causal relation between Gse1 knockdown and the lethality 
phenotype actually exists. 
  The last and the most important conclusion is that the phenotyping of the mice 
should be continued by investigating the presence or the absence of any similar or 
non-similar phenotypes after breeding with Cre mice. This represents the logical 
method to confirm our results in the ‘Knockout-first’ mice. Additionally, finding out the 
exact function of the studied gene (Gse1 in our case) and in which biological 
processes it is involved represents very essential step. Only that can prove with high 
reliability that the observed lethality was actually caused by the change in the 
expression of Gse1 gene, taking into consideration that several possible genomic 
mechanisms may be involved in this phenotype. Intrestingly, it was recently reported 
that the short sequence of LoxP or FRT sites, not only the neomycin cassette with its 
promoter, can cause unpredicted off-target effects far away from the targeted gene, 
indicating that we should be very careful by interpreting any phenotype in these 
transgenic mice (Meier et al. 2010). 
  Therefore, we started breeding the heterozygous mice with FLP mice to get rid of 
the trapping cassette. This will leave the animals with the mutant allele Gse1tm1c, 
which only differs from the wild type allele by the presence of one FRT and two LoxP 
sites, restoring thereby the normal expression of the gene. In order to do that ROSA-
FLPe mice were used, which contain the ROSA26 promoter that is supposed to 
guarantee moderate and ubiquitous expression of FLP-recombinase in all tissues of 
embryos and adult mice (Casola 2010; Giel-Moloney et al. 2007; Nyabi et al. 2009). 
According to our genotyping results, we obtained mosaic mice in the first generation 
after breeding with FLPe mice, where the FLP-recombinase was not efficient in all 
cells. Similar findings were described before for Cre and FLP mice, and especially for 
FLPe-recombinase (enhanced FLP), which has less recombining efficiency 
compared with FLPo-recombinase (optimized FLP) (Farley et al. 2000; Ryder et al. 




  However, in the following generation after breeding the mosaic mice with wild type 
mice, we were able to identify pure heterozygous mice for the mutant allele Gse1tm1c 
without FLP-recombinase, indicating that the recombination of the FRT sites occurred 
in the germ line of the parent. Only these mice are suitable to be used for generating 
and phenotyping the mice with Gse1tm1c allele without any possible off-target effects 
due to the presence of the FLP-recombinase cassette inside their genomic DNA. 
Phenotyping these mice should not show any difference compared with wild type 
animals. What should also be noticed in this context is that our genotyping protocols 
were suitable to distinguish between the mosaic and non-mosaic mice after breeding 
with FLP mice without redundancy or contradiction in the results. That was also 
confirmed by performing additional PCR using the primers LacZ_2_small_F and 
LacZ_2_small_R to further ensure the complete deletion of the trapping cassette 
from the genome of the mice from the second generation. The success after all these 
steps in establishing this mice strain represents therefore another valuable result 
from this study. 
  In addition to the previously shown efficient in vivo generating of the mice with 
Gse1tm1c allele, which will be used later to produce the null allele Gse1tm1d, we also 
performed an experiment to get the LacZ-tagged null allele Gse1tm1b in vitro. This 
was performed using Cre-recombinase-adenovirus and fibroblasts isolated from the 
kidneys of heterozygous and wild type adult mice (fibroblasts isolated from other 
organs such as heart or from the skin of the embryos were also used but their 
survival before or after the transduction were not sufficient for establishing this 
protocol). Our results, along with the quality control tests performed by us and by the 
providing company of the mice, represent adequate evidence for the conditionality of 
the ‘Knockout-first’ allele.  
  As previously mentioned, Gse1 gene has a circular RNA isoform in mouse 
generated from the same exon as in human, which therefore may be functional (Jeck 
et al. 2013; Lasda and Parker 2014; Memczak et al. 2013). In our study, a protocol to 
detect the circular RNA of Gse1 was established, and a difference in the expression 
level of this circular RNA was observed among mice from different genotypes. That 
might contribute to the observed lethality in the homozygous mice, as circular RNA 
can play the role of miRNA sponge. We were able to show that the RNA of the 




RNase R and not reverse-transcriped by oligo (dT). This is considered as an 
adequate proof for the circularity of this RNA (Lasda and Parker 2014). These 
experiments were important to be performed because the detection of a scrambled 
exon by outward-facing primers does not necessarily mean that we detect circular 
RNA. The proof about the presence of a scrambled exon, which only means that the 
sequence of the detected RNA is not in the same order compared with the 
corresponding genome, is not sufficient evidence for its circularity, as this could also 
exist in RNA with linear form. That can happen because of DNA rearrangements, 
tandem duplications in the DNA or trans-splicing (Figure 4.2) (Guo et al. 2014; Lasda 
and Parker 2014; Salzman et al. 2012).  
 
                            
                                                                    
                          
                                              
Figure 4.2: Possible mechanisms for generating scrambled exons detected by 
outward-facing primers (Adapted and modified from Lasda and Parker 2014).   
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  The resistance of circular RNAs to the exonuclease RNase R can further confirm 
the circularity, because these RNAs have no 5′and 3′ends. This causes relative 
enrichment of the circular RNAs in the treated samples compared with untreated 
samples, as only linear RNAs are degraded by RNase R treatment (Jeck et al. 2013; 
Salzman et al. 2012; Suzuki and Tsukahara 2014). The second proof for the 
circularity, which was provided in our study, was the depletion of the scrambled exon 
in oligo (dT)-reverse-transcription-primed samples compared with samples prepared 
using random hexamers. Such results could not be obtained if we were detecting 
linear RNAs containing this scrambled exon, including that generated by DNA 
rearrangements, tandem duplications or trans-splicing (Guo et al. 2014; Jeck et al. 
2013; Lasda and Parker 2014). Other methods are described to provide additional 
evidences for the presense of circular RNAs, such as Northern blot with probe 
complementary to the circularized exon, or virtual Northern as described in some 
studies. That depends on the fact that circular RNAs will migrate faster in the gel due 
to their smaller size compared with their normal corresponding linear RNAs, or 
compared with the trans-spliced transcripts which may be even larger than normal 
transcripts (Jeck et al. 2013; Memczak et al. 2013). Another suggested method is 
TRAP electrophoresis using solidifying agarose mixed with RNA, which will make the 
circular RNAs trapped, and only the linear RNAs will be able to migrate into the gel 
(Hansen et al. 2011).  
  After confirming the circularity of the detected scrambled exon, we found in our 
study that Gse1 circular RNA is expressed more in the embryonic RNA samples from 
the homozygous compared with the wild type animals. That was proved using 
specific TaqMan probe for the junction between the end and the beginning of the 
scrambled exon. These findings need to be further investigated by testing more 
samples from other embryonic and adults mice tissues, as the circular RNA is also 
described to have variable expression among different tissues (Bachmayr-Heyda et 
al. 2015; Lasda and Parker 2014). Another method to confirm the results regarding 
the upregulation of the circular RNA in homozygous samples is needed. Northern blot 
as a semi-quantitative analysis is helpful to achieve this purpose (Hansen et al. 2013; 
Memczak et al. 2013, Salzman et al. 2012).  
  In the future, we should certainly also investigate the mechanism behind the 




controlled on the first hand by the presence of complementary sequences, which 
cause pairing between the introns flanking the circularized exon or exons, inducing 
thereby the circularization. On the other hand, other pairing events between 
complementary sequences within these flanking introns, which are mediating the 
normal splicing, are in competition with the pairing between introns (Jeck et al. 2013; 
Zhang et al. 2014). Therefore, one explanation for the observed upregulation of the 
circular RNA can be that pairing within the intron downstream of the circularized exon 
is disrupted due to the insertion of the trapping cassette in this particular location, or 
pairing between the two introns around this exon is augmented. Another mechanism 
can be the lack of self-regulatory effect exerted by the linear isoforms of Gse1 that 
can control the splicing process of the pre-mRNA, and this cannot be confirmed or 
excluded based on our results. However, we showed that the organ with the lowest 
expression of the circular RNA among the tested organs in the mouse was the liver, 
which also had high expression of linear RNA isoforms (depending on the results 
obtained using the primers m.Gse1-F and m.Gse1-R, which are supposed to detect 
linear isoforms only). The heart showed on the opposite relatively high expression of 
the circular RNA, and the lowest expression of the linear isoforms. This may suggest 
the presence of a tissue-specific mechanism controlling the ratio of the circular/linear 
isoforms of Gse1 gene.    
  We tried also in this study to investigate whether the circular RNA of Gse1 is 
functional or not. The most studied function for circular RNAs in general is their role 
as miRNA sponge. It was shown by Hansen and his colleagues that one circular 
RNA, called ciRS-7 or CDR1as, which arises from the antisense transcript of CDR1 
gene, can modulate the activity of one miRNA called miR-7. This process is mediated 
by sequestering miR-7, as ciRS-7 has more than 70 conserved seed matches for this 
miRNA. Similar role was also described for another testis-specific circular RNA, 
which comes from the murine Sry (Sex-determining region Y) gene (Hansen et al. 
2013). Other suggested functions for circular RNA are the regulation of alternative 
splicing by competing with other splicing options and altering the structure of the 
remaining pre-mRNA splice, which can simply have different function or no function 
at all (Ashwal-Fluss et al. 2014; Lasda and Parker 2014). They might also be able to 
bind to different RNA-binding proteins, as delivery vehicles or as regulators for their 




  The expression results of the group of genes tested in our study; Foxp4, Thy1, 
Actn4, Wnt1, Kmt2d and Tfap2b are considered as a first and essential step to prove 
that the circular RNA of Gse1 is functional as a miRNA sponge, representing another 
novelty for our research. In order to do that, we followed the strategy of identifying the 
miRNAs that may be sequestered by the circularized exon of Gse1 according to the 
database miRBase (http://www.mirbase.org/search.shtml). Thereafter, the miRNA, 
mmu-miR-6968-5p, which showed the best match for its seed region with our circular 
RNA, was chosen. Previous genes were analyzed as they are the top 6 genes on the 
list of possibly targeted genes by this miRNA depending on the database miRDB 
(http://mirdb.org/miRDB/).  
  According to our results, most of these genes showed no difference in the 
expression level between homozygous and wild type embryos, and only one gene, 
Thy1, showed a significant decrease in the homozygous samples. However, this 
change is in the opposite direction to the expected change according to the 
hypothesis that the upregulated circular RNA of Gse1 works as a sponge for the 
miRNA mmu-miR-6968-5p, inhibiting thereby its suppressive activity. The last gene, 
Tfap2b, was almost significantly upregulated in the RNA samples from the 
homozygous embryos, which may provide the first evidence for the rightness of this 
hypothesis. Other experiments are certainly needed to prove the causal relation 
between the increased expression of the circular RNA, and the upregulation of 
Tfap2b. These can include overexpressing the circular RNA of Gse1 or knocking it 
down using siRNA designed to target the sequence formed by the backsplicing of the 
circularized exon (Hansen et al. 2013; Jeck et al. 2013). After that, we can investigate 
whether a corresponding change will happen in the expression level of Tfap2b or 
another possible target.  
  It is important to mention here that the negative effect of miRNAs on the target 
genes can be mediated through two distinct mechanisms, which are translational 
repression and/or mRNA degradation (McDaneld 2009; van Rooij 2011). This means 
that it may be insufficient to use qRT-PCR for investigating the expression of the 
genes that can potentially be targeted by the miRNA mmu-miR-6968-5p. It is possible 
that this miRNA does not induce the mRNAs of those genes to be degraded, but it 
may only suppress the translation of their proteins. Therefore, we need also to 




some genes, by which only the protein level is altered due to the upregulation of the 
circular RNA, and consequently its augmented role as a sponge for miRNAs. 
Interestingly, it was also found that the effect of miRNAs on gene expression is not 
always negative. According to the cell conditions and the recruited micro-
ribonucleoproteins, some genes were found to be upregulated by one miRNA and 
downregulated by another; the same miRNA can also cause increase or decrease in 
the expression of its target genes (McDaneld 2009; Valinezhad Orang et al. 2014). 
This makes the interpretation of our results even more complicated, as we should at 
first define the basic response of the suspected genes to the studied miRNA in each 
cell condition. That can be achieved by transfectig the cells with miRNA mimics, and 
identifying thereafter the change pattern in the expression of targeted genes as it was 
done in the previously mentioned work of Hansen and his colleagues (Hansen et al, 
2013). The importance of the circular RNA as miRNA sponge can then be 
determined by modulating the expression of this circular RNA and investigating any 
potential alteration in the basic change pattern induced by this miRNA.                   
  Reviewing the literature about the previously mentioned 6 genes showed interesting 
results. Tfap2b gene, which was found in our study to be almost significantly 
upregulated in the samples from homozygous embryos, is a transcriptional factor that 
is important for the development of the aortic arch and ductus arteriosus. It was 
shown to be mutated in Char syndrome, which includes PDA, facial dysmorphysm 
and hand anomalies (Zhao et al. 2011). Additionally, in another study about knockout 
mouse model for the gene CITED2 (CBP/p300-interacting transactivator with ED-rich 
tail 2) cardiac defects were reported. CITED2 gene was found to be essential for the 
normal activation of the three isoforms of Tfap2 (Tfap2a, Tfap2b and Tfap2c) by 
EP300 and CREBBP. Mutations in CREBBP gene are responsible for Rubinstein-
Taybi syndrome, where HLHS is described as one of its cardiac abnormalities, 
suggesting that a part of the observed defects in this syndrome can be related to 
Tfap2b gene (Bamforth et al. 2001). 
  Interestingly, all the previous results led us back to the point where we started, 
which is HLHS, where KIAA0182 was found to be mutated. This could be the first 
clue regarding the role of KIAA0182 gene in the development of HLHS, which 
supports further the hypothesis about the genetic etiology of this disease. As it was 




the evidences regarding the involvement of any of these genes are still not 
sufficiently conclusive. It was suggested before that HLHS may have a 
heterogeneous genetic etiology with a complex pattern of inheritance and 
penetrance, another hypothesis was that the accumulation of several mutations or 
rare variants is necessary to cause the disease. The exact determination of the 
involved genes can be helpful to understand the molecular mechanism behind HLHS, 
and possibly to make the right decision regarding the management plan (Grossfeld et 
al. 2009; Iascone et al. 2012).  
  We should keep in mind in this context that in spite of the improvement in surgical 
and medical care, the five-year survival rate for HLHS remains only 50-70 % after 
surgical repair. The outcome in these patients is strongly related to their 
characterstics, such as gestational age and genetic susceptibility (Feinstein et al. 
2012). One possible surgical approach for HLHS is the strategy of two-ventricle 
repair for the patients with patent mitral and aortic valves and mild hypoplasia in the 
left ventricle, as it was shown that left ventricle can resume growing in some cases 
after birth (Minich et al. 1997). The left ventricle in this approach may not be able 
later to support the systemic circulation, making the other choice of single-ventricle 
repair safer for the surgeon. However, the information about long-term prognosis 
after single-ventricle palliative repair including Fontan operation are still not 
completely promising, as the complications of “failing Fontan” are challenging, and 
may be increased in HLHS patients who underwent this operation (Feinstein et al. 
2012). That makes it clearly essential to define the exact etiology, and genetic cause 
if possible, for this disease, which can help to decide the most suitable treatment plan 
for each patient, taking into consideration the great heterogeneity of this syndrome. 
The therapeutic decisions can be better guided by developing some criteria regarding 
the genetic etiology of the disease and its pathogenesis, not only according to the 
anatomic phenotype (Grossfeld et al. 2009).   
  EndMT was also described before to be involved in the formation of EFE tissue in 
HLHS (Xu et al. 2015a), and understanding the role of KIAA0182 in this process may 
also have important therapeutic implications in HLHS or other diseases in general. 
Therefore, we started to study the importance of KIAA0182 knockdown using in vitro 
model for EndMT. According to the findings in our study, KIAA0182 gene (or Gse1 in 




and MCEC cells, suggesting a role for this gene in regulating this process. The 
upregulation of SNAIL and α-SMA upon KIAA0182 inhibiting could mean that it is 
involved in suppressing EndMT in endothelial cells. These results can be further 
confirmed by treating the endothelial cells with TGF-β after downregulating our gene 
of interest KIAA0182 and then comparing the response of these cells with that of 
control cells. This can be optimally performed using endothelial cells isolated from the 
mice with Gse1 null allele, but establishing an endothelial cell line with stable 
KIAA082-shRNA expression by virus transduction represents another useful option. 
We tried to establish this method before but it is not completely successful until now 
due to the short survival of the transducted endothelial cells and their low response to 
TGF-β after virus infection, especially in the cells of late passages. One interesting 
point to be remembered in this context is that GSE1 protein may be a component in 
CoREST complex (Hakimi et al. 2003; Yang et al. 2011; Yokoyama et al. 2008). This 
complex is reported to be recruited by SNAIL to inhibit the expression of E-cadherin 
during EMT (Lin et al. 2010), and it may be also similarly involved in EndMT. 
Therefore, another important experiment to be performed is Co-immunoprecipitation 
(Co-IP), which can help to prove the involvement of GSE1 protein in this complex, 
possibly as a regulator or as another transcriptional factor that recruits CoREST 
complex to the targeted genes. 
  The results of the AAC operation in the heterozygous and wild type animals should 
have helped us to get better understanding for the role of Gse1 in EndMT process 
and in cardiac fibrogenesis in general, but they were inconclusive. We could not 
detect any difference between the two genotypes regarding the heart weight, the 
systolic function, the systolic and diastolic dimensions, the hypertrophy or the fibrosis 
in the left ventricle. Several negative factors can be involved in that; first of all the 
decrease in the expression of Gse1 in the hearts of the heterozygous animals may 
not be adequate to cause any difference regarding the previously mentioned 
parameters, especially using such small sample size. Second, the results of the AAC 
and sham operations were analyzed only two weeks after the surgery. It may be 
possible that waiting for 4 weeks could have enabled us to detect more fibrosis in the 
AAC groups, as it was done in previous studies (Jiang et al. 2007; Takahashi et al. 
2007; Xu et al. 2015b; Zeisberg et al. 2007b), which could have made a potential 




  At last, the results of the operation were not consistent, as it was shown by the high 
variance in the fibrosis ratio, the ejection fraction and other echocardiographic 
parameters (Figure 3.28). This may be the consequence of the heterogeneity among 
the operated mice regarding the age and the pressure gradient across the 
constriction, especially in the heterozygous groups (Figure 3.27). Unfortunately, the 
high mortality of the operation in this study (35% compared with 16-20% in previous 
studies, which could be explained by the higher age of our mice) (Jiang et al. 2007; 
Takahashi et al. 2007) resulted in such small and heterogeneous cohort of animals. 
Therefore, that can be insufficient for investigating the effect of Gse1 downregulation 
on cardiac fibrogenesis in vivo, which represents, in addition to the other previously 
mentioned problems, a clear limitation in this study that needs to be managed in the 
future. 
  Another important limitation is that the expression results of GSE1 protein as 
estimated by Western blot are not completely trustable. Both Gse1 antibodies shown 
in previous section, among others tested, did not give a band with the expected size 
for GSE1 protein (around 140 kDa), which could be also explained by protein post-
translational modifications (PTMs) or by the presence of different isoforms for GSE1 
protein with unexpected sizes. In fact, all commercially purchased antibodies for 
Gse1 were not used in any previous study, and all of them were tested for Western 
blot and for immunofluorescence staining using different protocols, but it was not 
possible to find a specific and reliable one, especially for staining. The low trapping 
efficiency in the mice did not enable us to use them as a validation tool for the 
specificity of the antibody, which is necessary before interpreting the expression 
results of GSE1 protein, and Gse1 circular and linear RNAs to decide the major 
player in the observed phenotype.  
  Another critical task to be done in the future, in addition to the generation of the 
Gse1 null allele on genomic level, is to determine the expression profile of Gse1 in 
different tissues during several stages of embryonic development. This can be 
performed taking advantage of the presence of LacZ reporter in the trapping 
cassette, which will be expressed under the control of Gse1 promoter in homozygous 
and heterozygous mice. That will definitely help us to know when and where this 
gene is active in the embryo, and what the consequences of trapping are, which 




  The last thing to be remembered is that we started this study because of a 
heterozygous mutation in KIAA1082 gene found in a child with HLHS. Therefore, 
even if we are hopefully able to answer all the questions asked before regarding the 
function of this gene and the effect of its downregulation in vivo and in vitro, further 
experiments should be performed to find out the answers regarding any possible 
relevance of the mutation itself. This can be accomplished using endothelial cells and 
cardiac myocytes derived from iPSCs, which can be differentiated from fibroblasts 
obtained from that child. All these answers represent important pieces, and not 
necessarily interchangeable, in the puzzle to be solved in order to understand the 





















Objective: Hypoplastic left heart syndrome (HLHS) is one of the most severe 
congenital heart diseases. The genetic etiology for this syndrome was strongly 
suggested by several previous studies, and a lot of genes were suspected to be 
involved in its pathogenesis. De novo mutation in KIAA0182 gene (Gse1 in mouse) 
was found in this disease, but its exact role in HLHS or any other biological process 
is still to be determined. The aim of this research is to investigate the consequences 
of KIAA0182 downregulation in vivo and in vitro. Methods: The ‘Knockout-first’ 
design was used in this study to produce supposedly null allele of Gse1 
(Gse1tm1a(EUCOMM)Wtsi) in mouse model by disrupting its function on expression level. 
Human coronary arterial endothelial cells (HCAEC) were used to explore the role of 
KIAA0182 in endothelial to mesenchymal transition (EndMT), which was found 
previously to play a role in the development of endocardial fibroelastosis in HLHS. 
Ascending aorta constriction (AAC) was performed in mice as a model for cardiac 
fibrosis in vivo to confirm the results observed in vitro. Results: After several quality 
control tests to prove the correct targeting of Gse1 by the trapping cassette and to 
confirm its integrity, the genotyping results of 134 newborn mice from several matings 
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